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FUNCTIONAL REMODELING OF THE CARDIAC GLYCOME
THROUGHOUT THE DEVELOPING MYOCARDIUM
Marty L. Montpetit
ABSTRACT
Cell surfaces are replete with complex, biologically important glycans responsible
for multiple cellular functions including cell adhesion and cellular communication.
Proper protein glycosylation is essential for normal development and often
pathologies are marked by altered glycosylation. Here, data showed that the
auxillary subunit, β1, modified voltage-gated Na+ channel (Nav) gating in an
isoform-specific, sialic acid dependent, and saturating manner. The regulated
activity of the hundreds of glycogenes (glycosylation-associated genes) is
responsible for protein glycosylation; this could result in a glycome of thousands
of glycan structures. Microarray analyses indicated that glycogene expression
was highly regulated throughout the heart during development. Specifically,
>59% of glycogenes were significantly differentially expressed among neonatal
and adult atrial and ventricular myocytes. Quantitative-PCR of individual genes
confirmed the microarray analyses. Such substantial regulation of glycogene
expression likely results in changes in glycan structures attached to cell surface
proteins. To confirm this, myocyte glycan profiles were determined and
compared among neonatal and adult atria and ventricles using mass
spectrometry. The data predicted marked differences in glycan structures among
myocyte types, indicating that the glycome is remodeled throughout the heart
ix

during development. To address the question of whether the remodeled glycome
can impact cardiac function, action potentials and Nav activity were measured
and compared under conditions in which glycogene expression was regulated.
That is, atrial and ventricular myocytes were isolated from control mice and from
mice in which the polysialyltransferase, STX, was knocked out. STX is
expressed in the neonatal atria, and is essentially absent in neonatal ventricle.
Action potential waveforms and Nav activity measured in atrial myocytes were
impacted by STX expression. No changes in ventricular action potential
waveform or in Nav activity were observed; as expected since STX is not
expressed in the ventricle. The magnitude of the atrial action potential and the
rate of depolarization were decreased in the absence of STX. Further, Nav
gating was shifted consistently in the depolarized direction in STX knockout atrial
myocytes. Together, these data indicate that the glycome is tightly controlled
and regulated in the heart, and proper glycosylation is essential for normal
myocyte function.

x

CHAPTER 1
INTRODUCTION
Heart disease is the leading cause of death among U.S. citizens1. Accounting for
over 27% of deaths in 2004, heart disease caused 100,000 more deaths than
any other cause1. The cardiac action potential is formed through the coordinated
gating of voltage-gated ion channels. Conduction of the action potential
throughout the heart leads to cardiac contraction. Slight alterations in ion
channel function (likely through cardiac remodeling) are associated with many
cardiac maladies including heart failure, myocardial infarction and hypertension.
Although significant work has been devoted to understand variations in cardiac
waveform, this is the first to describe how a remodeled glycome could impact
cardiac excitability.

Cardiac remodeling impacts cardiac function
Changing the expression of proteins and therefore the cellular processes in
which they are involved is termed remodeling. Cellular remodeling is
characteristic of normal development2-20 and pathologies21-52. Cardiac
remodeling is evident in development as the human prenatal heart rate is
commonly over 150 beats per minute which slows to an average of 72 beats per
minute in the adult. Sympathetic innervation and ion channel remodeling are
considered responsible for the changing heart rate53-57. In the adult mouse
1

Figure 1.1. Ionic basis of the cardiac action potential.

Figure 1.1. Schematic of human action potential waveforms in atria (blue) and
ventricle (red) and the major ion currents creating these waveforms. Purple
indicates the current is involved in both cell types. Known or presumed channels
are noted to the right of each current. Figure from Pond and Nerbonne, 200158.
2

Figure 1.2. Action potential waveforms throughout the heart.

Figure 1.2. Examples of the various action potential waveforms throughout the
cardiac conduction and contractile systems. Differential expression of ion
channel subunits is assumed to be responsible for these changes in action
potential waveform. Action potentials are displaced in time to reflect the temporal
sequence of propagation through the heart. SA, sino-atrial; AV, atrio-ventricular;
RV, right ventricle; LV, left ventricle. Figure from Nerbonne, 200059.
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myocardium, ion channel expression changes between the atria and ventricle
(Figures 1.1 and 1.2) and within various locations throughout the heart (Figure
1.2) leading to different action potential (AP) waveforms58,59. Figure 1.1 shows
the difference between the typical atrial and ventricular AP, the currents that
constitute the AP, and the expression of the ion channels believed responsible
for those currents. Figure 1.2 shows the various action potential waveforms
present throughout the heart which are different due to a change in ion currents.

In addition to physiological changes in heart function, cardiac pathologies may
result from both electrical and structural remodeling. In atrial fibrillation, sodium
currents (INa), calcium current (ICa), and the transient outward potassium current
(Ito) are reduced due to a decrease in the mRNA levels of channels responsible
for these currents50,60. The decrease in ICa is likely responsible for shortening of
the atrial action potential and the decrease of Ito results in loss of the ability of the
heart rate to adapt to physiological changes. Atrial fibrillation is also
accompanied by atrial enlargement, loss of myofibrils, accumulation of glycogen,
alteration of mitochondrial size and shape, fragmentation of sarcoplasmic
reticulum and dispersion of nuclear chromatin61,62. It is unclear whether atria are
enlarged as a cause or as a result of atrial fibrillation63.

Arrhythmias are the leading cause of death in patients with heart failure (HF)64.
Recent studies indicate that AP prolongation is a contributing factor to
arrhythmias associated with HF65-69. Although the exact mechanism for AP
4

prolongation is not agreed upon, modulated K+, Na+, and Ca2+ currents have
been identified65-73. Ionic currents are typically remodeled in HF through
changes in the density and/or the expression of various isoforms of ion
channels65-73. Furthermore, glycosylation is reduced in both hamster74 and
mouse73,74 models of cardiac heart failure suggesting that glycosylation
machinery is altered.

Regulation of glycan biosynthesis is essential for normal physiology
Cell surfaces are replete with glycan structures essential for proper development
and normal function of living organisms with roles in protein trafficking, immunity,
cell adhesion, receptor activation and endocytosis75 (Figure 1.3). Protein
function may be modulated by glycans through at least two mechanisms: 1) By
altering the function of the protein’s conjugate and, 2) By conferring biological
activity to its conjugate. Glycans act as antigens on a variety of cells and
activate the immune response as evidenced by the 1996 cholera pandemic of
Bengal, India which was caused by Bengal 139 Vibrio cholerae76. This was the
139th identified strain of vibrio cholerae each of which had unique glycan
structures. Exposure to and subsequent antibody formation of a single strain
does not protect the host from any of the 138 other strains. Furthermore the A,
B, O and AB blood types are dictated by the glycans attached with the O blood
type lacking glycan structures and A and B each with unique structures. As
discussed with Vibro cholerae, glycans act as antigens; therefore, type B blood
can not be administered to those with O or A types. Recent studies have
5

Figure 1.3. Roles of glycans in cellular functions.

Figure 1.3. Cellular function is regulated by glycans through various
mechanisms. The influence of glycans on cellular function ranges from protein
folding to cellular communication. Figure from Ohtsubo and Marth, 200675.
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reported the ability to change blood type B to O by simply altering the glycan;
thus circumventing the immune response when, for example, type B blood is
transfused into one with blood type A77. In these examples, the cell is not
inherently immunoreactive, the glycans confer these attributes.

In mammals, proteins and lipids are glycosylated in the endoplasmic reticulum
and golgi apparatus where enzymes catalyze oligosaccaride formation from nine
monosaccarides78,79. Glycosylation is non-template driven, unlike the DNA
template necessary for protein synthesis, and requires expression of glycogenes
that comprise 1-2% of the human genome78-82. Protein glycosylation refers to
both N-glycans and O-glycans. N-linked glycosylation is attached to an
asparagine residue; hence, the “N-linked” nomenclature. N-linked glycosylation
requires the specific sequence of Asn-Xaa-Ser/Thr and sometimes Asn-Xaa-Cys
where Xaa is any amino acid except proline. O-glycosylation lacks a specific
conserved sequence; instead several enzymes may catalyze the first sugar
residue attached to serine or threonine. Glycosylation is a highly ordered
process where the product of one enzyme is the substrate for the next and where
catabolic glycosidase enzymes are as important as anabolic glycosyltransferase
enzymes.

N-glycan synthesis (summarized in figure 1.4) is initiated in the cytoplasm where
the first sugars are added to a lipid dolichol. This dolichol-glycan structure then
translocates into the lumen of the endoplasmic reticulum where further branching
7

Figure 1.4. Overview of N-glycan biosynthesis.

Figure 1.4. Synthesis of N-glycans from initial attachment to dolichol through
assembly and processing of N-linked glycans. Molecular defects of known CDG
types are indicated where known etiologies occur. N-glycan assembly is initiated
in the ER lumen by transferring two GlcNAc residues (blue squares) to Dol-P and
completed in the lumen of the golgi. Mannose (red circles), glucose (yellow
triangles), fucose (grey triangle), galactose (green rhombus), sialic acid (pink
diamonds). The mouse symbol designates a knock-out mouse of that enzyme, in
red are yeast or CHO cells expressing specific enzymatic defects. Adapted from
Marquardt and Denecke, 200382.
8

9

and sugar addition occurs. Eventually the glycan structure is transferred en bloc
from dolichol to the asparagine residue of a newly synthesized protein. Within
the endoplasmic reticulum, the glycan structures are extended and trimmed
several times until the glycoprotein is transferred to the golgi. Final processing of
the glycan takes place in the golgi. The process includes addition of negatively
charged sialic acid residues and when polysialyltransferase enzymes are
expressed, sialic acids attach to other sialic acids (termed poly sialic acid) adding
substantially more negative charges to a single structure 83.

The glycome is defined as the full set of glycan structures produced in the
body84,85, and is composed of thousands of glycan structures that perhaps is
larger than the proteome75. Glycan diversity is accentuated by several factors
which can be divided into two types: protein determined and cellular factors
(Figure 1.5). The protein itself can only be N-glycosylated where specific Nlinked sequences are present and accessible according to tertiary protein
structure (including protein phosphorylation), and is commonly located
extracellularly78,79. Sites located within the membrane, intracellularly or where
the extracellular 3-dimensional structure prohibits access to those sites, will not
be N-glycosylated. Also, the rate at which the protein traverses through the
glycosylation pathway may alter the final glycan structure. The second factor is
cellular in nature. The repertoire of glycogenes expressed varies from cell type
to cell type and, as this study indicates, throughout development. Furthermore,
glycosidase and glycosyltransferase enzymes are considered to be constitutively
10

Figure 1.5. Regulation of glycan expression.

Figure 1.5. Glycan structure expression is regulated through various cellular
mechanisms. These include (1) glycosyltransferase and glycosidase gene
transcription, (2) nucleotide sugar synthesis and transport to the ER and golgi
(sugar transporters not depicted), (3) enzymatic structure modification through
phosphorylation, (4) enzyme competition for identical substrates, (5) enzyme
trafficking and access to substrates, (6) secretion of catalytic domains resulting
from proteolysis within the lumen of the golgi (7) glycan turnover at the cell
surface by endocytosis. Figure from Ohtsubo and Marth, 200675.
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active when expressed, yet competition between enzymes requiring a specific
substrate further contributes to glycan diversity.

Glycogene expression and glycan structure are tightly regulated in different
tissues, through development and in disease states. Comelli et al. reported that
bone marrow, thymus, lymph nodes, spleen, lung, testes, kidney, liver and brain
all had unique glycogene expression and glycan populations86. Further,
glycogene and glycan profiles of immune tissues (bone marrow, thymus,
lymphnodes, and spleen) were more similar to each other than non-immune
tissues (lung, testes, kidney, liver and brain) as non-immune tissues were more
similar than immune.

Glycogene expression and glycan structure are also tightly regulated through
development of various tissues. As shown here and in Ishii et al., glycogene
expression is altered throughout the developing myocardium and in the
developing cerebral cortex, respectively4. Glycan profiles are distinct in each
developmental stage of each tissue.

Various disease states including Down syndrome, Huntington’s disease,
glaucoma, and heart failure reveal a change in glycogene expression and
possibly glycan structure profiles compared to healthy tissues28,39,74,75. Although
altered glycan arrays may be present in these disease states, they may or may
not cause, contribute to or exacerbate conditions.
12

Minor changes in glycogene expression may have a major impact on glycan
structure and organism physiology75,82,85,87. The role of glycosylation is
vast, spans every tissue, and is involved in numerous physiological
processes. Ongoing research in glycobiology focuses on immune responses,
neuron tracking, ligand binding, and cancer indicating the wide range of functions
of glycans in normal and pathophysiology75,86,88,89.

Improper glycosylation results in pathologies that range from mild disease to
lethal 85. Common effects seem to target neuronal, cardiovascular and muscular
systems. Congenital disorders of glycosylation (CDG) are autosomal recessive
disorders in which a single glycogene is mutated or missing or there is no known
cause (as shown in figure 1.4). To date, 28 unique forms of CDG have been
identified, 16 N-glycosylation associated, 6 O-glycosylation associated, 4 N- and
O-associated and 2 involving glycolipids90. Recently, a new category has been
identified and classified as CDGs of hyperglycosylation defects. CDG tends to
affect individuals differently; for example, one patient of CDG-Ih was effectively
treated with a low fat diet and essential oil supplements while four others suffered
fatal maladies90. With such a vast range of symptoms presented, diagnosis is
difficult and with many unknown causes of death in infants, it is likely that many
CDG patients are never identified. One common thread through the many CDGs
is symptoms consistent with decreased excitability such as hypotonia
and decreased metabolic activity. Also, all types of CDG have glycans with
13

reduced sialylation despite different enzymes ablated. In fact, isoelectric
focusing of serum transferrin is the most common assay to diagnose CDG,
testing for a decrease in tetra-, penta- and hexa- sialylated transferrins replaced
by mono-, di- and tri-sialylated transferrins.

Chagas disease is an ailment affecting over 18 million with thousands of new
cases reported each year91. Chagas disease is characterized by progressive
chronic fibrotic myocarditis and degeneration of tissues innervated by the
autonomic nervous system, most commonly marked with cardiac abnormalities
such as arrhythmias and cardiac insufficiency92. Trypanosoma cruzi, the agent
of Chagas disease, is a protozoan most commonly transmitted through insect
bites, but can be transmitted through blood transfusions as well93. T. cruzi
releases a sialidase to cleave negatively charged sialic acid residues from host
cells to incorporate with itself. It is believed that this is the etiology of the major
symptoms of Chagas. Changing the level of sialylation may contribute to cardiac
arrhythmias and insufficiency possibly through modification of ion channel
function.

Ion transport is the basis for cellular communication
Ion transport across the membrane of excitable tissues is essential for proper
cellular and tissue function. Cellular membranes are essentially impermeable to
ions; thus, ion transport requires assistance in the form of membrane proteins.
These proteins can be divided into several groups, transporters, pumps and ion
14

channels. Transporters allow ions to move across the membrane with other
solutes e.g. the sodium/glucose transporter. Pumps require the use of energy to
move ions across the membrane. Ion channels are water filled pores that allow
ions to flow through the membrane down their electrochemical gradient when
open. There are four types of ion channels, leak, ligand gated, stretch activated,
and voltage gated channels. Leak channels are considered constitutively active
(open) and contribute to maintenance of the resting membrane potential of a cell.
Stretch activated ion channels require the membrane to physically stretch the
channel to an open state while ligand gated channels open in response to a
ligand (i.e., a neurotransmitter) binding to its' extracellular surface. Voltage gated
ion channels gate in response to the depolarization and repolarization of the cell
membrane.

Cardiac contraction is the result of orchestrated ion channel function
The cardiac action potential is the concerted opening, inactivation, and closing of
many types of voltage gated ion channels, the Na+/K+ ATPase pump, and
possibly some ligand gated ion channels (summarized in Figure 1.1 and 1.6).
The result of the cardiac action potential is cardiac systole. The cardiac action
potential of contractile myocytes is divided into 5 distinct phases. Phase 0 is the
depolarization of the cellular membrane by opening of voltage gated sodium
channels (Nav) which allows sodium ions to move down their electrochemical
gradient and into the cell. Phase 1 begins at the height of cellular depolarization
and is marked by a sudden repolarization of the cell. This occurs when voltage
15

Figure 1.6. Schematic of a typical cardiac action potential.

Figure 1.6. The cardiac action potential is shown, with ionic currents responsible
for each phase listed. Figure from Keating and Sanguinetti, 200194.

16

gated sodium channels inactivate and sodium can no longer traverse the
membrane and around the same time, voltage gated potassium channels open to
allow potassium ions to exit the cell (Ito); thus, causing a short, rapid
repolarization. As Ito diminishes, voltage gated calcium channels open to initiate
phase 2. Influx of calcium ions is approximately the electrical equivalent to
the efflux of potassium ions leading to a flat segment in the cardiac action
potential termed the "plateau." In phase 3, calcium channels inactivate and
another population of slowly activating potassium channels open which causes
the final repolarization and hyperpolarization of the membrane. This
hyperpolarization of the membrane is essential for the voltage-gated ion
channels to recover from inactivation. In phase 4, mostly leak and ligand gated
ion channels are open to maintain the resting membrane potential and allow
more channels to return to a closed position so the cell is prepared for the next
action potential and resulting systole.

The structure of Nav dictates channel function
Voltage gated sodium channels (Nav) are transmembrane proteins which open in
response to membrane depolarization to selectively allow sodium ions to pass
though95. Nav are composed of a single polypeptide chain approximately 220kD
and is composed of 24 transmembrane segments subdivided into 4 homologous
domains composed of 6 transmembrane segments each (Figure 1.7). Each of
the 6 transmembrane segments are unique, yet have homologous segments in
the other 3 domains. The S5 and S6 domains line the pore with an extracellular
17

Figure 7. Schematic of the voltage-gated sodium channel structure.

Figure 7. Schematic of voltage-gated sodium channel alpha and beta subunits.
(a) A characteristic alpha subunit with four homologous domains, each consisting
of six alpha helical transmembrane segments is illustrated with the β1 subunit.
The S5 and S6 (shown in green) of each domain are considered the pore forming
segments. The loop connecting the S5 and S6 dips into the pore and forms the
selectivity filter (designated by white circles). Note that both proteins are
glycosylated (represented by ψ). Blue circles in the intracellular loops of
domains III and IV mark the inactivation gate IFM motif and its receptor (h,
inactivation gate); P, phosphorylation sites. (b) A hypothetical three-dimensional
structure of the Nav channel α-subunit compiled from electron micrograph
reconstructions. Figures adapted from Yu et al. 200396.
18

S5-S6 linker that dips into the pore. This pore forming loop is essential to proper
channel selectivity, where the specific amino acid sequence of DEKA (aspartate,
glutamate, lysine and alanine) defines the channel as sodium specific. When this
sequence is changed to the calcium channel sequence of EEEE, the channel
allows calcium to pass while preventing sodium entry. Although the remaining
structure is currently under debate, there is consensus that the remaining
transmembrane segments are located peripherally to the pore. The S4 segment
is considered to be the voltage sensor since every third amino acid is a positively
charged arginine or lysine and the whole segment moves in response to
membrane depolarization. Movement of the S4 segment causes a
conformational change and the channel to gate allowing sodium to enter into the
cell. Also of note is the intracellular linker of domains III and IV which contains
the hydrophobic amino acid sequence; IFM (isoleucine, phenylalanine and
methionine) which has been implicated in fast inactivation.

The tertiary and quaternary structure of voltage gated ion channels has been the
topic of recent debate within the scientific community as an alternative
hypothesis has arisen from crystallography work on the voltage gated potassium
channel which shares significant homology with Nav97-100. Cartoons of both
models are shown in figure 1.8. The conventional theory, as proposed through
studies from the past 25 years, has the S4 segment located within a water filled
column formed by the other segments of the same domain. The S5 and S6
segments form the pore while S1-S3 surround the S4. The S4 segment moves
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Figure 1.8. Two competing theories for voltage-gated ion channel gating.

Figure 1.8. Cartoon depicting two models of S4 segment movement in response
to a change in membrane potential (ΔV). (+) signs represent positively charged
amino acids within the protein structure. Figure from Jiang et al. 2004.97
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towards the extracellular surface in a perpendicular manner to the cellular
membrane in response to membrane depolarization. In the model proposed by
Jiang et.al., the S4 segment forms a paddle-like structure with the S3
segment peripheral to the pore which rotates through the lipid bilayer towards the
extracellular surface and again causes a conformational change in the poreforming segments to open the channel97. Both theories have two important
similarities. First, the positively charged amino acids, composing the S4
segment, move towards the extracellular surface and second, this movement
results in channel gating. Since the introduction of the paddle theory in 2003, the
scientific community has been vigorously debating these theories with evidence
supporting the traditional theory101-108 and other data supporting the paddle
theory97-100,109-113.

Post-translational modifications may alter ion channel function
The surface potential theory predicts that charges closely associated with the
membrane adjacent to voltage gated ion channels contributes to channel
gating95. The idea is based upon electrostatic attraction of the voltage sensor by
negative charges closely localized to the channel. The source of these charges
include charged lipids of the cell membrane, charged amino acids of the protein
itself or a closely associated protein, ions present in the extracellular fluid and
negatively charged sialic acid residues capping glycan structures.
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Voltage gated ion channels are heavily post-translationally modified through fatty
acylation, phosphorylation, nitrosylation, sulfonation, and glycosylation. Of these
posttranslational modifications, glycosylation is the highest proportion with
upwards of 30% of the final channel mass being glycans114-116. A fully
glycosylated and sialylated channel could have as many as 100 sialic acid
residues attached to a single channel114-116. Each ion channel is differently
glycosylated based upon number and location of potential N-linked sites and the
other factors involved in N-glycosylation described above.

The impact of glycosylation, particularly sialic acids, on ion channel gating has
been the focus of numerous studies73,117-128. These studies report that
glycosylation can directly alter gating of voltage-gated sodium and potassium
channels in an isoform specific manner. For example, in CHO cells, Nav1.4
gating is sialic acid sensitive whereas the gating of Nav1.5 does not change in
response to the altering level of sialic acids117,118. Nav1.4 is more heavily
glycosylated than Nav1.5 likely due to the number of glycosylation sites with
mature glycans attached.

Nav1.5 is the predominate sodium channel isoform expressed in mouse cardiac
tissue and commonly is considered the cardiac isoform3. Studies have
concluded that Nav1.5 is the isoform responsible for phase 0 of the cardiac action
potential indicating that Nav1.5 gating initiates and propagates the cardiac action
potential129. Nav1.5 has the same basic structure as other voltage gated sodium
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channels and is putatively heavily glycosylated with 13 potential glycosylation
sites117.

A recent study of Nav function in neonatal and adult cardiomyocytes showed that
neonatal ventricular Nav required a ~10mV greater depolarization to gate than
does neonatal and adult atrial and adult ventricular Nav123. Following
desialylation through neuraminidase treatment, neonatal atrial and adult atrial
and ventricular Nav gated similarly to untreated (and neuraminidase-treated)
neonatal ventricular Nav.

Furthermore, investigators determined that Nav1.5

was similarly expressed throughout the developing myocardium and β1 did not
contribute to the changes. Western blot analysis revealed that neonatal and
adult atrial and adult ventricular Nav had higher levels of sialylation than did
neonatal ventricular Nav. Regulated glycogene expression is likely responsible
for the various levels of Nav glycosylation observed, and the resulting changes in
Nav gating. This suggests that the cardiac glycome may be regulated throughout
the heart during development.

This study was designed to determine whether the glycome is remodeled
throughout the developing myocardium and whether the remodeled glycome can
affect excitability. Glycans, more specifically the negatively charged sialic acid
residues commonly capping glycan structures, modulate gating of voltage gated
ion channels in both a cis (glycans attached to the alpha subunit) and trans
(glycans attached to an auxiliary subunit) manner as reported in chapter 3. The
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level of glycosylation of Nav changes throughout the developing myocardium and
in cardiac failure74,123. The change in glycogene expression throughout the
developing myocardium is described in chapter 4 and chapter 5 illustrates the
correspondingly diverse N-glycan profiles. Finally, chapter 6 suggests that
cardiac excitability can be altered through the regulation of a single glycogene.
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CHAPTER 2
MATERIALS AND METHODS
Chinese Hamster Ovary (CHO) Cell Culture and Transfection
Pro5 and Lec2 cells were grown as described previously130. Briefly, cells were
plated onto 35 mm culture dishes at 25-50 % confluence. Following a 24 h
incubation, cells were then exposed to a 1 ml Opti-MEM (Invitrogen) medium
containing 8 µl lipofectamine (Invitrogen) and 1-2 µg DNA. Following a 5-24 h
incubation at 37°C in a 5% CO2 humidified incubator, the medium was replaced
with CHO medium consisting of Dulbecco's modified Eagle's medium (DMEM;
Mediatech) supplemented with 25 mM Hepes, 15% fetal bovine serum (FBS;
Mediatech), and 100 U ml-1 penicillin and 100 µg ml-1 streptomycin. Growing
medium included the same antibiotics, 10% FBS, and alpha Minimum Essential
Medium (αMEM) with (Pro5) or without (Lec2) ribo- and deoxyribonucleosides
(Invitrogen). Electrophysiological recordings began 68-76 h post-transfection,
selecting cells expressing GFP.

Vector Construction and Mutagenesis
The rNav1.2 open reading frame (ORF) inserted into pRC-CMV (Invitrogen) was
a gift of Dr. Alan Goldin. The hNav1.7 cDNA ORF was inserted into pcDNA3.1.
Expression vectors containing hNav1.4 and hNav1.5 were as previously
described118. hβ1 was subcloned into the bicistronic vector, pIRES2-EGFP
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(Clontech), to ensure expression of β1 through visual inspection. The hβ1 mutant
(hβ1-ΔN) was created using the GeneEditor (Promega) site-directed mutagenesis
kit. hβ1 was cloned into pBluescript vector (Stratagene) as a template. Each
asparagine residue initiating an external N-linked consensus sequence, NX(S/T),
was mutated to a serine residue through sequential mutagenesis. The constructs
were sequenced to confirm successful mutagenesis. hβ1-ΔN was then subcloned
into pIRES2-EGFP for co-expression experiments. hβ1 and hβ1-ΔN were amplified
using PCR with the following oligonucleotides 5'TCCGGCCACCTGGACGCCCG-3' and 5'-GCGCAGCACGCGCCGCGCAG-3'.
PCR products were subcloned into pcDNA3.1/V5-His TOPO TA expression
vector (Invitrogen). Both ORFs were subsequently subcloned into pEGFP-N1
(Clontech) to generate C-terminal, GFP-tagged hβ1 and hβ1-ΔN constructs.

Electrophysiology and Data Analysis
Sodium Current Recordings
Sodium currents were recorded using the whole cell patch clamp technique
described previously117,118. The combination of an Axon Instruments 200B patch
clamp amplifier with a CV203BU headstage (Axon Instruments, Foster City, CA).
Pulse acquisition software (HEKA) running on an 800 MHz Pentium III PC
computer (Dell Computers) was used to generate pulse protocols. The resultant
analog signals were digitized using the ITC-16 analog to digital converter
(Intsrutech, Great Neck, NY).
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Whole cell patches were formed using techniques previously described 131.
Electrodes were back-filled with electrode solution and manipulated to close
proximity to the target cell. Slight negative pressure was applied to the electrode
and giga-seals formed between the cell and electrode tip and a short, rapid
increase in negative pressure provided electrical access to the interior of the
target cell. Pulse protocols are explained explained later. All data were recorded
at least 5 minutes after attaining whole cell access to ensure dialysis of electrode
solution.

External recording solutions consisted of (in mM): 224 Sucrose, 22.5 NaCl, 4
KCl, 2.0 CaCl2, 5 glucose, and 5 Hepes. Intracellular recording
(electrode) solutions contain (in mM): 120 sucrose, 60 CsF, 32.5 NaCl, and 5
Hepes. Both solutions were titrated with 1 N NaOH to pH 7.4 at room
temperature. All solutions were filtered using 0.2 µm filters (Invitrogen)
immediately prior to use. For the Ca2+ perfusion studies, the Ca2+ calcium
concentration was reduced in the external solution to 0.2 mM. Seals were
formed in the bath solution containing 2.0 mM Ca2+. The cells were first perfused
with 2.0 mM Ca2+ bath solution and followed by perfusion the 0.2 mM Ca2+ bath
solution to determine directly the shift in Va with a 10-fold change in external Ca2+
concentration. All of the data shown were recorded at least 5 min after attaining
whole cell configuration to assure complete dialysis of the intracellular solution.
All of the solutions were filtered using Gelman 0.2-µm filters immediately prior to
use.
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Pulse Protocols
Conductance-Voltage (G-V) Relationship
Pulse protocols were used as previously described 117. A holding potential of 120 mV was applied to the cell and stepped from -100 to +70 mV in 10 mV
increments for 10 ms. Consecutive pulses were initiated every 1.5 s and leak
subtracted using the P/4 method which steps negatively from the holding
potential to eliminate any leak current. At each potential, steady-state whole-cell
conductance was determined by measuring the peak current and dividing by the
driving force (difference between the membrane potential and the observed
reversal potential). Single Boltzmann fits of the data determined maximum
conductance and the average Va ± SEM were determined from this fit.
Normalized data from the Boltzmann fits were averaged with remaining cells of
the same type and an averaged conductance-voltage curve was determined
using the following Boltzmann relation fit to the data:
Fraction of maximal conductance= [1+(exp-(V-Va/Ka))]-1,
where V is the membrane potential, Va is the voltage of half activation, and Ka is
the slope.

Steady-State Inactivation Curves (hinf)
Cells were prepulsed for 500 ms from the holding potential (-120 mV) to
potentials ranging from -130 to -20 mV in 10 mV increments, followed by a +60
mV pulse for 5ms and returning to the -120 mV holding potential. Currents from
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each cell were normalized to the maximal current (determined through a single
Boltzmann fit), averaged with other cells of the same type and again fit to a single
Boltzmann relationship (eq. 2) from which Vi (voltage of half inactivation) and the
slope were calculated.
Fraction of maximum current = [1+(exp-(V-Vi/Ki))]-1,

Recovery from Inactivation
Cells were held at -120 mV membrane potential, pulsed to +60 mV for 10 s,
and stepped to the recovery potential for 1-20 ms in 1 ms increments. The
potential was then stepped again to +60 mV for 10 ms. Peak currents from the
two +60 mV pulses were compared to determine the fraction of current measured
during the second pulse which represents the fraction of channels that recovered
from inactivation during the recovery pulse. Fractional current was plotted as a
function of the recovery time between the two test pulses of 60 mV. Single
exponential functions were fit to the data to determine the time constants for
recovery from inactivation, trec.

Measurement of Inactivation gating kinetics
Inactivation gating kinetics were determined from attenuating currents (90-10%)
of traces used for G-V relationships which were fit to a single exponential
function.
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Neonatal and Adult Cardiac Tissue Isolation
Neonatal and adult atria and ventricle tissue were isolated for microarray,
quantitative PCR, western blot analysis and mass spectrometry. Neonatal mice
and adult mice were euthanatized and whole hearts removed and placed in
Dulbecco's phosphate buffered saline. Atria were gently removed from the
remaining heart and ventricles were dissected away from the base of the heart
with great care taken to ensure only atria and ventricles were removed. The
remaining portions were discarded. Tissue intended for microarray and
quantitative PCR studies was transferred to RNase Later (Sigma, St. Louis, MO)
and incubated for minimum one hour. Tissue intended for western blot and mass
spectrometry studies was snap frozen in liquid nitrogen to prevent protein
degradation and stored at -80oC.

mRNA Isolation
Heterogeneous populations of litter-mate animals were isolated for microarray
testing. Neonatal samples were each composed of 7-9 animals (14-18 atria or
ventricles) yielding approximately 25-28 mg of tissue. Adult samples were each
composed of 4 animals (2 male and 2 female) aged 10-12 weeks yielding
approximately 25-28 mg of tissue. Tissue was homogenized by dounce and
isolated following RNeasy manufacturer protocols (Qiagen). Beckman
Spectrometer was used to determine final RNA concentration.

30

Microarray
Three RNA samples each of neonatal and adult atria and ventricle were sent to
the Consortium for Functional Glycomics Gene Microarray Core E for microarray
analysis. Samples were amplified and biotin labeled using the Bioarray High
Yield RNA transcript labeling kit (ENzo Life Sciences, Farmingdale, NY).
Hybridization and scanning of the glycogene-chip, GLYCOv2, were performed
according to Affymetrix's recommended protocols (Affymetrix, Santa Clara, CA).

Microarray Analysis
The GLYCOv2 chip was created by the Consortium for Functional Glycomics and
produced by Affymetrix (Affymetrix, Santa Clara, CA). This chip was designed
that each probeset consists of 11 perfect match and 11 single base mismatch
probe pairs (Table 2.1).

The intensities from each perfect match were compared to corresponding
mismatch pair. Invariant set normalization of the data was performed using the
DNA-Chip (dChip) Analyzer (www.dchip.org) software package for probe-level
and high level analysis of gene expression microarrays. Hierachical clustering
and class comparison was accomplished using Biometric Research Branch
(BRB) Array Tools v3.2.2. Heatmaps were generated using the dChip program.
Class comparison used a p-value cutoff of 0.05 and a multivariate permutation
based false discovery rate calculation preset at 10% with 80% confidence level.
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Table 2.1 Breakdown of probesets on GLYCOv2
Probesets In
Triplicate

Probesets In
Duplicate

Single
Probesets

Total genes
transcript
targets

Total
Probesets

Total Human

503

426

101

1030

2462

Total Mouse

443

363

119

925

2174

0

0

46

46

46

2001

4682

Total Other (control)
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Quantitative PCR
Three RNA samples each of neonatal and adult atria and ventricle were reversetranscribed to cDNA using Superscript II Reverse Transcriptase (Invitrogen)
following manufacturer's protocols. Briefly, 1ug of total RNA, 100µM dNTPs and
100ng of random hexameric primers (Invitrogen) were incubated at 65oC for 5
minutes then placed on ice. First strand buffer and 10 mM dithiothreitol (DTT)
were added and incubated at room temperature (25oC) for 2 minutes. Finally,
200 µM Superscript II reverse transcriptase was added to the mixture and
incubated for 10 minutes at room temperaturefollowed by 42oC for 50 minutes
and 70oC for 15 minutes. cDNA is ready for use in real time reactions.

Primer sets were designed using PrimerQuest (IDT) and are shown below.
Primer sets were tested for efficiency and precise amplification using dilution
curves. Quantitative PCR was performed on 12 gene products including HPRT
and β-actin as controls. Each primer set was run in triplicate for each sample.
SYBR Green PCR master mix (Superarray), primers and cDNA were combined
in one well of a 96 well PCR plate (Rio-Rad) and covered using RT-PCR optical
tape (Bio-Rad). PCR products were detected in real time using the iCycler iQ
detection system (Bio-Rad) with PCR conditions of 5 minutes at 95oC followed by
40 cycles of 30 sec at 95oC, 30 sec at 60oC and 30 sec at 72oC. Relative
expression levels were reported using the ΔΔCT method of analysis where
triplicate threshold values of a single gene are averaged and compared to the
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control (either HPRT or β-actin) then this ΔCT value is compared to the ΔCT of
another sample.
Quantitative PCR primer sequences
ST3Gal3

CTG TGA TGA AGT GGC AGT CG

CTC GCT GGA TGT TGT CTG TC

ST3Gal5

AAA GTC CCA CTC CAG CCA AAG C

GTG TAG CCA AGA CAA CGG CA

STX

AGC CAG CCT CAT CCA AAT G

TAT CCT TCT CCG CAT CCA AG

ST6Gal1

GAC CAG GAG TCA AGT TCA GCG T

AGA AGA CAC GAC GGC ACA CT

ST8Sia6

TGC TGC TCC TCC TGC GTA T

TAT GTG CTG TTC CTG GTG CGT G

ST6GalNAc6

AAC AAA GAG CAG CGG TCA GC

GTT GCC GAG GAT AGG GAA GTA GG

Versican

TGG CTG TGG ATG GTG TTG TG

TGC TCT GGG CTT GCT ATG AC

HPRT

GCA GTA CAG CCC CAA AAT GG

GGT CCT TTT CAC CAG CAA GCT

B-actin

CCA ACC GTG AAA AGA TGA CC

CCA GAG GCA TAC AGG GAC AG

Glycan Screening
Glycan Isolation
N-glycans were isolated as previously described132. Cardiac tissue was
homogenized in 0.5% SDS tris buffer and dialyzed in 12-14 kDa cut-off dialysis
tubing in an ammonium hydrogen carbonate solution (50 mM, pH 7.4) for 48
hours. Once dialyzed, samples were lyophilized. Reduction and
carboxymethylation of samples were carried out by incubation in 0.5ml of 2
mg/mL DTT in deoxygenated tris buffer (0.6M, pH 7.4) for 45 minutes at 37oC
followed by addition of 0.5 ml of 12mg/mL iodoacetic acid in tris buffer (0.6M, pH
7.4) and incubation for 90 minutes at room temperature in the dark. Reaction
was terminated by dialysis for 48 hours and the sample was lyophilized. Samples
were then digested in 1 mL of a 50mM ammonium hydrogen carbonate solution
(pH 8.4) with approximately 2 mg of TPCK treated bovine pancreas trypsin at
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37oC for 16 hours. The sample was purified through a Sep-Pak C18 conditioned
with 5mL methanol, 5mL 5% (v/v) acetic acid in water 5mL propan-1-ol and 30
mL of 5% (v/v) acetic acid followed by collection of 3mL of 20% (v/v) and 40%
(v/v) propanol in 5% (v/v) acetic acid. These fractions are pooled and lyophilized
followed by digestion with 3 units of N-glycosidase F (PNGase F) in 200 uL of
50mM ammonium hydrogen carbonate (pH 8.4) at 37oC for 20 hours. The
digested sample was purified through a pre-conditioned Sep-Pak C18 (5mL
methanol, 5mL 5% acetic acid, 5mL propan-1-ol and 15 mL of 5% acetic acid),
eluted with 5mL of 5% acetic acid.

Glycan derivatization
N-glycans were prepared for mass spectrometry by chemical derivatization using
the sodium hydroxide procedure133. 5 pellets of sodium hydroxide and 3mL of
dry DMSO were crushed together in a glass mortar. 1mL of the resulting slurry
was added to the dry sample in a glass tube followed by 0.5mL of methyl iodide.
The mixture was vigorously mixed on an automatic shaker for 15 minutes at
room temperature. The reaction was quenched by addition of water,
Permethylated N-glycans were extracted with 1mL of chloroform and washed
with 3mL of water several times. The organic phase was dried under a stream of
nitrogen. Derivatized and dried glycans were then purified through a preconditioned Sep-Pak C18 (5mL methanol, 5mL water, 5mL acetonitrile, 15 mL
water) and eluted with 15%, 35%, 50% and 75% (v/v) acetonitrile in water.
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Mass Spectrometry
Mass spectrometry was performed through the Consortium for Functional
Glycomics and the methods were described previously132. The permethylated
sample was dissolved in 10 µl of methanol, and 1 µl of dissolved sample was
mixed with 1 µl of 2,5-dihydroxybenzoic acid (20mg/mL in 70:30 (v/v)
water:methanol), spotted onto a metal plate and dried under vacuum. MALDIMS and MALDI-MS/MS data were acquired using a Perseptive Biosystems
Voyager-DETM STR mass spectrometer in the reflectron mode with delayed
extraction and a 4800 MALDI-TOF/TOF (Applied Biosystems, Damstadt,
Germany) mass spectrometer respectively. The collision energy for MALDIMS/MS experiments was set to 1kV and argon was used as collision gas.

Cardiomyocyte Isolation for Electrophysiology
The cardiomyocyte isolation protocol was adapter from a method described
previously134. Neonatal (postnatal day 2-3) mice we rapidly euthanized and
hearts excised and placed in 0 Ca2+ Tyrode’s Solution. Atria and ventricles were
carefully separated and digested in 260 units Type I collagenase (Sigma, St.
Louis, MO)/ mL 0 Ca2+ Tyrode’s Solution at 37oC for 40 minutes. Cells were
centrifuged at 160 g for 5 minutes and the supernatant replaced with fresh
collagenase solution. Cells were gently triturated and incubated at 37oC for 30
minutes followed by centrifugation at 160 g for 5 minutes. The supernatant was
replaced by CHO media (DMEM supplemented with 10% Fetal Bovine Serum
(Gibco) and 100 U/ml penicillin and 100mg/ml streptomycin (Gibco), triturated,
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and incubated at 37oC for 20-40 minutes to stop digestion. Again the cells were
centrifuged for 5 minutes at 160 g and plated on laminin-coated 35mm dishes in
fresh CHO media.

Cardiomyocyte Electrophysiology
Sodium Current Recordings
Recording techniques were described above. External recording solutions
consisted of (in mM): 20 NaCl, 10 TES, 5 KCl, 1 CaCl2, 5 CsCl, 10 glucose,
and 100 choline chloride adjusted to pH 7.35 with CsOH. Intracellular recording
(electrode) solutions contain (in mM): 20 NaCl, 10 TES, 2 MgCl2, 2 CaCl2, 20
EGTA, and 105 CsF adjusted to pH 7.35 with CsOH. All solutions were filtered
using 0.2 µm filters (Invitrogen) immediately prior to use.

Action Potential Recordings
Myocytes were patched and recorded in external solution (in mM): 135 NaCl
5 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, 10 glucose, pH 7.4. Patch pipettes were
filled with a solution with the following constituents (in mM): 110 K-Asp; 20 KCl,
10 NaCl, 4 ATP-Mg, 10 HEPES, pH 7.3. APs were recorded at room
temperature (22-25 °C) using an Axopatch 200B amplifier (Axon Instruments)
and pCLAMP 9 software (Axon Instruments). APs were triggered by a 2-ms
injection of a depolarizing current at a frequency of 1 Hz. Analysis of APs was
performed using Clampfit 9 software (Axon Instruments, Foster City, CA).
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Transgenic mouse
The STX knockout mouse was provided through collaboration with Dr. Jamey
Marth, University of California San Diego. Neonatal mice were 2-3 days postnatal and adult mice were 10-12 weeks post-natal.

Data Analysis
Sodium current electrophysiological data were analyzed using Pulse/PulseFit
(HEKA) and Sigmaplot 2001 (SSPS Inc.) software. Action potential data were
analyzed using Clampfit (Axon) and Sigmaplot 2001 (SPSS Inc). Figures were
produced using Sigmaplot 2001 (SPSS Inc), Microsoft Excel (Microsoft), or Corel
Draw (Corel).
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CHAPTER 3
THE β1 SUBUNIT MODULATES Nav GATING IN AN ISOFORM-SPECIFIC,
SIALIC ACID-DEPENDENT MANNER

Cardiac remodeling often involves modulating ion channel expression and/or
function. One mechanism of this remodeling likely involves regulated expression
and function of Nav alpha and beta subunits. With ten identified Nav alpha
isoforms, changing expression of these isoforms would modify ion currents135.
The role of β1 was not conclusively established with theories of the role of β
including nodal stabilization, cellular localization, functional expression, kinetics
and voltage-dependence of channel gating136. Previous studies report that Nglycans alter function of some Nav alpha isoforms. Here we report β1 subunit
sialic acids alter the voltage dependence of Nav gating.

The β1 subunit external domain is essential for correct modulation of sodium
channel gating and is the site of four potential N-glycosylation sites137. At least
three of these four sites are thought to be glycosylated in the mature
protein. Published reports agree that β1 causes a hyperpolarizing shift in the
voltage dependence of inactivation and in several studies, activation gating was
also shifted in the hyperpolarized direction by β1138-145.
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Voltage gated sodium channel α and β subunit isoforms each have a unique
glycosylation signature determined through their differing number and location of
N-glycosylation sites. In an attempt to determine how N-glycans alter Nav
function, four isoforms, the adult skeletal muscle isoform (Nav1.4), the cardiac
isoform (Nav1.5), a peripheral nerve isoform (Nav1.7), and a brain isoform
(Nav1.2), were expressed in the fully glycosylating Pro5 and reduced sialylating
Lec2 cell lines. Nav1.4 and Nav1.5 were previously reported 117,118 and Nav1.2
and Nav1.7 were studied here for the first time. Table 3.1 and figures 3.1-3.4
indicate that Nav1.5 and 1.7 are not sensitive to α sialic acids; whereas, Nav1.2
shows a small, insignificant depolarizing shift in gating when sialylation is
reduced. Nav1.4 shows a significant ~14.6mV depolarizing shift in the absence
of sialic acids.

In an attempt to determine the role of the β1 subunit in voltage gated sodium
channel gating, we co-expressed β1 with each of the four Nav isoforms. When
co-expressed in the fully sialylating Pro5 cell line, β1 induced a hyperpolarizing
shift in all measured gating parameters of three of four α subunits. β1 did not
have an effect on Nav1.4 gating. These data generally agree with previously
published work with most studies indicating that β1 induces a hyperpolarizing shift
in the gating of various α subunits137,143,146-150.
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Table 3.1. The measured gating parameters for α±β1±sialic acid
Channel construct

n

Nav1.4 + SA
Nav1.4 - SA
Nav1.4 + β1 + SA
Nav1.4 + β1 - SA
Nav1.5 + SA
Nav1.5 - SA
Nav1.5 + β1 + SA
Nav1.5 + β1 - SA
Nav1.7 + SA
Nav1.7 - SA
Nav1.7 + β1 + SA
Nav1.7 + β1 - SA
Nav1.2 + SA
Nav1.2 - SA
Nav1.2 + β1 + SA
Nav1.2 + β1 - SA
hSkM1P1 + SA
hSkM1P1 - SA
hSkM1P1 + β1 + SA
hSkM1P1 + β1 - SA

9
9
11
9
13
10
11
9
10
9
12
9
9
10
12
9
10
8
9
11

Va
(mV)
-31.3 ± 2.0
-16.7 ± 1.7a
-29.2 ± 1.6
-16.3 ± 1.1a
-29.0 ± 2.2
-29.5 ± 1.6
-37.4 ± 1.6a
28.6 ± 0.9
-15.1 ± 1.2
-14.4 ± 1.7
-23.8 ± 1.8a
-13.4 ± 1.3
-14.6 ± 1.6
-11.7 ± 1.8
-20.8 ± 0.7a
-11.9 ± 1.0
-23.5 ± 2.3
-26.7 ± 1.2
-32.7 ± 2.0a
-24.0 ± 1.5

Vi
(mV)
-71.5 ± 3.3
-60.8 ± 1.5a
-70.0 ± 2.3
-63.1 ± 1.8b
-78.7 ± 2.5
-79.5 ± 1.9
-86.1 ± 3.2b
-78.8 ± 1.6
-70.0 ± 2.4
-70.0 ± 3.7
-76.2 ± 2.0b
-68.3 ± 1.5
-60.5 ± 3.1
-62.7 ± 3.1
-68.1 ± 2.7b
-62.2 ± 2.8
-70.4 ± 2.5
-68.8 ± 2.5
-75.9 ± 1.6b
-69.2 ± 1.5

τh
trec (-120 mV)
(ms)
(ms)
2.4 ± 0.4
1.8 ± 0.05
7.9 ± 1.1a 1.3 ± 0.03a
2.9 ± 0.5
1.7 ± 0.02
8.1 ± 0.2a 1.4 ± 0.03a
2.8 ± 0.4
4.0 ± 0.1
2.4 ± 0.2
4.1 ± 0.1
2.0 ± 0.1b
5.6 ± 0.3a
2.9 ± 0.2
4.1 ± 0.1
4.8 ± 0.8
5.5 ± 0.09
5.2 ± 1.2
5.5 ± 0.06
b
3.0 ± 0.4
7.8 ± 0.2a
5.1 ± 0.8
5.5 ± 0.2
3.3 ± 0.7
2.5 ± 0.08
3.1 ± 0.5
2.2 ± 0.04b
2.3 ± 0.3b 3.1 ± 0.07a
3.2 ± 0.6
2.2 ± 0.06b
3.4 ± 0.5
1.8 ± 0.07
3.4 ± 0.8
1.8 ± 0.05
b
2.3 ± 0.4
2.4 ± 0.06a
3.7 ± 0.6
1.9 ± 0.04

Table 1. The measured gating parameters for α±β1±sialic acid. The data are the
mean parameter values ± S.E. τh data were measured for Nav1.4, Nav1.5, and
hSkM1P1 at -40mV and for Nav1.2 and Nav1.7 at -30mV. Two-tailed Student’s t
test was used to determine the significance of β1 sialic acids comparing each
condition with the parameter measured for the fully sialylating α subunit alone.
Significance (p<0.1) demarcated with an (a) and highly significant (p < 0.005)
demarcated with a (b). Table from Johnson et al. 2004120.
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Figure 3.1. Alpha and β1 subunit sialic acids modify channel activation in an α
subunit dependent manner.

Figure 3.1. Conductance-voltage (G-V) relationships for four voltage-gated
sodium channel α subunits ± β1 as expressed in the fully sialylating, Pro5, and
reduced sialylating, Lec2, cell lines. The data are the mean normalized peak
conductance (G) ± S.E. at a given membrane potential and are shown as curves
that are fits of the data to single Boltzmann relationships. Data are summarized
in Table 1. Circles with solid lines, α subunit alone; squares with dashed lines,
α+ β1. Filled symbols, in Pro5 cells; open symbols, in Lec2 cells. A, Nav1.4. B,
Nav 1.5. C, Nav1.7. D, Nav1.2. Figure adapted from Johnson et al. 2004120.
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Figure 3.2. Alpha and β1 subunit sialic acids modify channel inactivation in an α
subunit dependent manner.

Figure 3.2. Steady state channel availability (hinf) curves for the four α subunits ±
β1 ± sialic acid. The data are the mean normalized peak current ( ) ± S.E.
measured during a maximally depolarizing test pulse following a 500-ms
prepulse to the plotted potentials. Lines and symbols are identical to those
described in figure 3.1. Figure from Johnson et al. 2004120.
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Figure 3.3. Alpha and β1 subunit sialic acids alter channel fast inactivation rates
in an α subunit dependent manner.

Figure 3.3. The rate of fast inactivation for the four α subunits ± β1 ± sialic acid.
The data are the means ± S.E. time constants for fast inactivation (τh) as a
function of membrane potential. Inset to C, representative normalized whole cell
Na+ current traces measured at –20 mV for Nav1.7. Note that the rate at which
the current attenuates (inactivates) is much faster in the presence of β1 sialic
acids, consistent with the observed shift in τh along the voltage axis. The scale
shown is for Na 1.7 + β1 + SA current traces, to which the other current traces
were normalized. Lines and symbols are identical to those described in figure
3.1. Figure from Johnson et al. 2004120.
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Figure 3.4. Alpha and β1 subunit sialic acids modify channel recovery from
inactivation in an α subunit dependent manner.

Figure 3.4. Time constants for recovery from fast inactivation (τrec) ± S.E.
measured for the four α subunits ± β1 ± sialic acid at three recovery potentials.
Inset to C, typical plot of the fractional recovery measured following a –120mV
recovery potential for Nav1.7 ± β1 ± SA. The data are the means ± S.E. fractional
current measured during a second depolarizing test pulse following the plotted
interval at –120 mV recovery pulses of various durations. The lines are
exponential fits of the data from which the τrec were determined. Lines and
symbols are identical to those described in figure 3.1. Figure from Johnson et al.
2004120.
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Due to the fact that β1 is heavily glycosylated, we tested the hypothesis that β1
sialic acids modulate Nav gating. β1 induced a hyperpolarizing shift in the gating
of three of the four α subunits studied when expressed in Pro5. This effect was
eliminated when expressed in the essentially non-sialylating Lec2 cell line as all
four α subunits gated the same as α expressed alone. β1 did not alter any gating
parameter of Nav1.4 under either sialylating or non-sialylating conditions. As
shown in figures 3.1-3.4, all effects of β1 on gating can be attributed to the sialic
acids attached to β1, since in the absence of β1 sialic acids, Nav gating is not
modulated.

In addition to N-linked glycosylation, sugars can be attached to serine or
threonine residues of membrane proteins termed, O-linked glycosylation.
Mutagenesis of the four N-linked glycosylation sites provides a method to
determine that N-linked sialic acids are responsible for modulating Nav gating.
The mutant β1 lacks all N-linked glycosylation, yet all other post-translational
modifications remain. As exhibited in figure 3.5, β1-ΔN (β1 with all N-glycosylation
sites mutated resulting in no N-glycosylation) had no effect on gating of any of
the Nav α subunits previously modulated by β1. Thus, we confirm that β1 N-linked
sialic acids are fully responsible for the observed shifts in Nav α gating.

Figures 3.1-3.4 showed that the heavily glycosylated Nav1.4 was sensitive to α
subunit sialic acids (cis effect), but not sensitive to β1 sialic acids (trans effect).
Conversely, the putatively lesser glycosylated Nav1.2, 1.5 and 1.7 were not
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Figure 3.5. β1 subunit sialic acids modify channel gating parameters in a
saturating manner.

Figure 3.5. Voltage-dependent steady state and kinetic gating for hSkM1P1 ±
β1± SA is shown. Circles, hSkM1P1 expressed alone; squares, hSkM1P1 + β1.
Filled symbols, in Pro5 cells; open symbols, in Lec2 cells. A schematic of
hSkM1P1 structure illustrates that the chimera consists of Nav1.4 with the less
glycosylated Nav1.5 DIS5-S6 loop replacing the Nav1.4 DIS5-S6. A, G-V
relationship. B, steady state channel availability. C, fast inactivation time
constants. D, time constants for recovery from fast inactivation. Figure from
Johnson et al. 2004120.

47

Figure 3.6. The impact β1 has on Nav gating is likely through electrostatic
interaction.

Figure 3.6. A bar graph of the observed hyperpolarizing shifts in Va for hSkM1P1
± β1± SA with a 10-fold decrease in external Ca2+ concentration used to
differentially screen external negative surface charges. Figure from Johnson et
al. 2004120.
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dependent on α subunit sialic acids, but β1 sialic acids modified their gating.
These data suggest that in this cellular system there may be a saturating limit to
the contribution of sialic acids to channel gating, with Nav1.4 sialic acids possibly
achieving saturation. Figure 3.6 further supports this theory by showing that
gating of a less glycosylated Nav1.4 chimera, hSkM1P1 (a generous gift from Dr.
A.L. George Jr.), is no longer dependent on α subunit sialic acids but is sensitive
to β1 sialic acids. These data suggest that by decreasing Nav1.4 sialylation
below saturating levels, β1 can impact channel gating. Thus, it appears that the
combined effects of cis α subunit DIS5-S6 and trans β1 subunit functional sialic
acids on channel gating are saturating.

The surface potential theory of voltage-gated channel gating is often assigned to
the phenomenon of negative external surface charges changing channel
gating. It has been established that increasing external Ca2+ concentrations
tends to shift Nav gating to depolarized potentials. Ca2+ tends to screen the
negative charges that contribute to the negative surface potential; thus,
minimizing the external negative charge sensed by the channel gating
mechanism. The voltage sensed by the channel gating mechanism becomes
more negative, moving away from the voltage of half activation and requiring a
larger depolarization to activate the channel. If sialic acids contribute to this
negative surface potential, channel gating will be more sensitive to external Ca2+
concentrations as the level of sialylation is increased. If β1 sialic acids contribute
to the surface potential, co-expression of β1 with hSkM1P1 (a reduced
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Figure 3.7. N-glycans are completely responsible for β1 effects on Nav gating.

Figure 3.7. G-V relationships for hSkM1P1 (A), Nav1.5 (B), Nav1.7 (C), and
Nav1.2 (D) under fully sialylated conditions alone or co-expressed with β1 or with
β1-ΔN. Filled circles with solid lines, α subunit alone (n = 9–13 for each); filled
squares with dashed lines, (n = 9–12 for each); filled triangles with dotted lines, α
co-expressed with β1-ΔN (n = 4–6 for each). Figure from Johnson et al. 2004120.
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glycosylated form of Nav1.4) in Pro5 cells should show the greatest sensitivity to
Ca2+. Figure 3.7 clearly indicates that the presence of β1 increases sensitivity to
external Ca2+ concentrations; thus, β1 sialic acids likely contribute to the negative
surface potential.

Discussion
To date, there have been many α and β subunit isoforms identified for the
voltage-gated sodium channel, each with unique glycosylation patterns that may
modulate sodium current118,128. Expression of α subunits and β subunits are
regulated over time and in disease states and can be processed differently
among cell types possibly as a mechanism to ensure proper cellular function151155

. The model in figure 3.8 suggests a scenario where Nav α and β1 subunit

combinations function differently and sialylation could change the location on the
curve as sialylation is changed.

As proposed by this model, various α subunit isoforms may function differently as
a result of their level of glycosylation as ten α isoforms have been identified each
with a unique putative glycosylation signature. β1 expression, as previously
described and in this study, alters some Nav channel α isoforms; hence, control
of β1 expression causes acute changes in functional sialic acids associated with
an α subunit possibly altering the gating of the α subunit.
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Figure 3.8. Model proposing the saturating effects of sialic acids on Nav gating.

Figure 3.8. Model predicting the possible saturating effects of α and β1 sialic
acids on Nav gating. (A) Possible interactions between Nav1.4 (highly
glycosylated) and hSkM1P1 (lesser glycosylated) α subunit and β1 sialic acids.
The data suggest that β1 sialic acids cannot contribute further to the gating of
Nav1.4 but do contribute to the gating of the other α subunits through an apparent
electrostatic mechanism. Thus, Nav1.4 shows ineffectual β1 sialic acids as
distant, whereas the hSkM1P1 illustrates that fewer α subunit functional DIS5-S6
sialic acids may allow β1 sialic acids to interact more intimately with the α subunit
and contribute to channel gating. (B) a theoretical G-V curve comparing
contributions to Va associated with various α and β1 combinations. The location
of each combination is not precise but is consistent with the data shown here.
Figure from Johnson et al. 2004120.
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β1 expression is regulated through development, commonly expressed at the
highest levels after 4 weeks of age156-159. β1 is a heavily glycosylated protein;
although, this level is different among the tissues in which it is expressed. If β1
glycosylation alters Nav α gating, then Nav would likely be modified differently in
each tissue in relation to the level of glycosylation. Here, we report the effect of
β1 on Nav gating can be entirely attributed to sialic acid residues.

A recent study of Nav function revealed a sialic acid dependent change in Nav
activity throughout cardiac development123. These changes were independent of
altered Nav protein expression as the same Nav α isoform was expressed in all
tissues studied and upregulation of β1 did not impact Nav function. Different
levels of glycosylation, through glycogene regulation, likely is responsible for
these changes and is the focus of the following two chapters.
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CHAPTER 4
GLYCOGENE EXPRESSION IS REGULATED THROUGHOUT THE
DEVELOPING MYOCARDIUM

Slight changes in ion channel function may lead to devastating maladies such as
myotonia, paralysis, epilepsy, long QT syndrome (LQTS) and arrhythmias
associated with heart failure129,148,160-180. One possible mechanism to modulate
Nav function is through alteration of the glycan structure. A previous report
indicated that cardiac Nav gating is altered in a cell-specific, glycosylation
dependent manner123. Furthermore, others report that glycosylation is altered in
disease states, some of which present with altered excitability28,29,73-75,87,88,92.
Thus, we determined that glycogene expression is regulated, and that the
glycome is remodeled. Then, we questioned whether and how these changes in
glycosylation might alter cardiac excitability.

Glycosylation abnormalities have been reported to occur in many disease states
including heart failure. Until recently, in depth studies of glycogene expression in
cardiac disease and non-disease states have been lacking. Here we present
and compare the glycogene expression profiles for four healthy cardiac tissues;
neonatal atria (NA), neonatal ventricle (NV), adult atria (AA) and adult ventricle
(AV). This investigation utilized the GLYCOv2 gene chip, a customized array
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designed by the Consortium for Functional Glycomics, containing 2174 probesets
targeting 942 mouse transcripts encoding proteins responsible for glycan
biosynthesis and glycan recognition, including glycan transferases, glycan
degradation proteins, proteins involved in nucleotide sugar biosynthesis, glycanbinding proteins, and transporters.

To determine the relationship among the four tissue types, we performed
hierarchical clustering from all probesets, glycosyltransferases, glycan
degradation proteins and nucleotide biosynthesis (Figure 4.1). High correlation
within each of the tissue types reveals minimal variability between replicates of
each tissue type. Independent clustering of each tissue type indicates the
glycogene profile is unique among the four tissue types.

Hierarchical clustering showed that glycogene expression profiles are unique for
each of the four tissue types and these differences are evident when displayed
as heat maps (Figure 4.2). Due to the lack of a control tissue studied, signals
from each gene target are averaged and all relationships are compared to this
average with red blocks indicating expression above the mean, blue
blocks below the mean, and white as the mean. Despite the differences of
overall glycogene expression, there are some important similarities to explore
further. The patterns observed provide insight into the changing expression of
glycogenes and their role in development, chamber specific expression or high
expression in only one tissue type (lower in the three other tissue types).
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Figure 4.1 Comparison of glycogene expression among samples.
A. Overall

B. Glycosyltransferases

C. Glycan Degradases

D. Nucleotide Sugar Synthesis
and Transport

Figure 4.1. Unsupervised hierarchical clustering analysis of glycogenes in the
developing murine myocardium. The dendrograms have been constructed using
center correlation and average linkage. Three biological replicates are shown for
neonatal atria (PA), neonatal ventricle (PV), and adult ventricle (AV) and two
biological replicates for adult atria (AA). (A) Overall glycogene expression. (B)
Glycosyltransferases. (C) Glycan degradases. (D) Nucleotide sugar synthesis
and transporters.
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Figure 4.2A. Glycosyltransferase expression throughout the developing
myocardium.
NA NV AA AV

NA NV AA AV

Figure 4.2. Heat maps displaying the relative gene expression levels among
each sample and cell type as measured from microarray data. Red indicates
upregulation compared to the mean of all samples for a given glycogene
whereas blue indicates downregulation and the individual glycogene mean is
white. (A) Glycosyltransferases. (B) Glycan degradases. (C) Nucleotide sugar
synthesis and transporter genes.
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Figure 4.2B. Glycan degradase expression throughout the developing
myocardium.
NA

NV

AA

AV
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Figure 4.2C. Nucleotide sugar synthesis and transporter gene expression
throughout the developing myocardium.
NA

NV

AA

AV
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Three distinct expression patterns were identified in the data presented here.
First, glycogene expression can be regulated developmentally. This is observed
in figure 4.2 where the neonatal tissues are blue or red and adult tissues are the
opposite color. Versican is developmentally regulated and is highly expressed in
the neonate and essentially absent in the adult. This is likely due to
the importance of versican in the development of the heart and its diminished
role in adults. On the contrary, ST3GalVI is also developmentally regulated, but
present in the adult and absent in the neonate.

Secondly, glycogene expression is also regulated in a chamber-specific manner
where genes are expressed above the mean in neonatal and adult atria and
below the mean in the neonatal and adult ventricle or vice versa. These changes
indicate that the genes involved are essential to normal atrial or ventricular
function but not both. Mannosidase-II is categorized with a chamber specific
expression pattern since it is expressed at much higher levels in the atria than
the ventricles.

The third expression pattern identified is the high (or low) expression of a
glycogene in one of the four tissue types compared to the other three. This effect
is likely a combination of the two patterns discussed previously where the gene is
developmentally expressed (i.e. only present in neonatal tissues) and in a
chamber specific manner (i.e. expressed only in the atria). The
polysialyltransferase, ST8SiaII (STX), has been shown to be expressed in
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various tissues in early developmental stages181,182, yet ST8SiaII is found to be
expressed only in the neonatal atria and is absent in the neonatal ventricle as
well as both adult tissues.

Glycogene expression is quite different among the four tissue types and is
regulated developmentally, in a chamber specific manner, or as a combination of
the two. Furthermore, changing the expression patterns of different enzymes will
alter glycosylation biosynthesis at various points throughout the process.

Each glycoprotein and glycolipid has a common core structure which is
elongated, possibly branched and eventually terminated. Figure 4.3 illustrates
these core structures for N- and O- glycans and glycolipids. For further insight
into the impact of a change in glycogene expression, four groups have been
created: core structure synthesis, termination, glycan degradation and
nucleotide sugar synthesis of which some genes are represented twice; once in
core structure synthesis and once in one of the other three groups.

Core Structures
As summarized in table 4.1A, most genes with roles in core glycan synthesis are
regulated in a chamber-specific or developmental manner, yet several have no
significant change in expression. Most of those genes involved which have some
change in expression are involved in the translocation of N-glycan structures
from the cytoplasm to the lumen of the endoplasmic reticulum. On the contrary,
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Figure 4.3. The three basic glycosylation structures.

Key:
GlcNAc
GalNAc
Glucose
Mannose
Galactose
Fucose
N

S/T

Cer

N-linked

O-linked

Glycolipid

Sialic Acid

Figure 4.3. Schematic of typical N- and O-linked glycans and glycolipids.
Dashed lines indicate core structures for each glycoconjugate.
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Table 4.1A mRNA levels encoding proteins involved in core structure synthesis.

Gene Name
N-Glycans
ALG13
DPM1
DPM2
GPI1(PIGq)
PIG-a
Pigb
PIGF2
Putative PIG-M
Defender against cell death protein1
Oligosaccharyltransferase 48
RibophorinI
RibophorinII
GNT1
GNT2
a-Mannosidase (Man2B1)
b-Mannosidase
MannosidaseII (Man2A1/ManII)
O-Glycans
Galnt1(ppGalNAcT1)
Galnt2(ppGalNAcT2)
Galnt3(ppGalNAcT3)
Galnt4(ppGalNAcT4)
Galnt6(ppGalNAcT6)
Galnt7(ppGalNAcT7)
Glycolipids
UDP-glucoseceramideglucosyltransferase
ceramide1--galactosyltransferase

NA

NV

AA

AV

154.6
417.1
407.9
391.6
76.8
51.5
66.5
151.6
1200.0
714.3
1083.9
603.0
473.2
390.3
406.6
320.1
279.4

154.4
444.4
341.7
410.8
70.6
47.4
67.2
153.6
1010.9
490.3
1023.0
436.9
517.3
366.3
307.7
332.0
192.9

153.6
407.9
308.5
436.3
54.5
65.6
63.6
159.0
1246.5
531.6
869.3
653.2
464.0
295.0
366.3
302.6
298.3

180.8
514.4
231.0
750.0
50.2
52.3
80.1
149.8
886.4
403.0
722.6
453.4
448.0
202.5
299.4
257.5
165.2

623.4

598.7

826.0

871.3
12.2
63.2
49.2
91.3

625.0
12.1
57.8
47.7
112.9

614.1
12.1
68.2
56.5
87.5

1046.
5
445.5
12.8
57.5
49.9
98.9

188.6
27.2

138.2
28.8

127.2
23.1

100.4
27.8

Table 4.1. Gene expression profiles of glycogenes directly involved in glycan
synthesis. Intensity signals were generated with the dChip v1.3 PM-only
algorithm and represent the mean of independently prepared samples. (A)
Proteins involved in core structure synthesis. (B) Sialyltransferases. (C)
Sulfotransferases. (D) Fucosyltransferases. (B,C,D) are considered terminal
glycosyltransferases. (E) Glycan degradases; (F) Nucleotide sugar synthesis
and transporters. NA, neonatal atria; NV, neonatal ventricle; AA adult atria; AV,
adult ventricle.
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Table 4.1B. mRNA levels encoding proteins involved in sialylation.

Gene Name
ST3GalI
ST3GalII
ST3GalIII
ST3GalIV
ST3GalV
ST3GalVI
ST6GalI
ST6GalII
ST6GalNAcI
ST6GalNAcII
ST6GalNAcIII
ST6GalNAcIV
ST6GalNAcV
ST6GalNAcVI
ST8SiaI
ST8SiaII
ST8SiaIII
ST8SiaIV
ST8SiaV
ST8SiaVI

NA
179.2
145.1
170.2
111.3
319.6
178.1
257.9
51.9
76.8
77.8
40.1
107.5
111.0
259.0
54.3
121.6
61.9
64.3
110.2
26.0

NV
142.1
121.9
177.1
126.9
266.6
190.5
139.1
54.1
82.4
88.1
39.9
118.3
111.9
304.4
61.6
48.3
64.3
209.7
106.0
65.1

AA
195.6
122.4
205.8
132.8
562.4
409.8
198.3
56.2
81.9
74.1
41.8
85.1
117.7
318.2
55.3
51.2
77.4
112.9
120.4
40.2
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AV
160.3
101.7
314.8
108.0
1061.3
372.6
82.0
53.0
80.4
76.4
49.7
94.8
98.6
403.3
63.4
41.1
107.9
226.7
98.5
105.2

Table 4.1C. mRNA levels encoding proteins involved in sulfation.

Gene Name
chondroitin4-O-SulfoT1
CS4ST-1
CS4ST-2
CS6ST-1
Gal3ST-1
Gal3ST-2
Gal3ST-4
GlcNAc6ST-1
GlcNAc6ST-2
GlcNAc6ST-3
GlcNAc6ST-4
HS2OST
HS3OST-1
HS3OST-3B
HS6OST-1
HS6OST-2
HS6OST-3
KS6ST-1
NDST1
NDST2
NDST3
NDST4

NA
178.2
68.9
146.3
66.4
67.8
50.7
15.0
79.3
155.3
34.0
79.8
354.5
169.6
66.9
186.7
53.9
58.0
284.2
112.7
131.5
34.5
43.6

NV
149.5
60.7
108.2
64.8
62.4
53.0
15.8
87.8
136.2
36.4
105.5
295.7
107.6
69.6
179.1
55.9
56.3
349.9
71.3
125.2
32.3
43.4
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AA
212.9
64.1
146.5
70.8
64.9
59.3
14.0
85.4
282.6
36.6
83.4
211.2
151.2
67.9
152.0
43.1
55.9
363.0
90.8
89.0
38.1
43.8

AV
144.3
46.5
103.3
71.5
49.3
45.9
18.8
74.5
195.5
35.3
96.6
157.1
105.1
61.3
155.4
45.3
58.3
528.3
54.4
93.6
40.5
43.9

Table 4.1D. mRNA levels encoding proteins involved in fucosylation.

Gene Name
Fut1
Fut2
Fut4
Fut7
Fut8
Fut9
Fut10
Fut11
Pofut1
Pofut2
Sec1

NA
128.3
57.6
34.3
79.7
218.0
11.0
70.8
216.4
133.8
302.9
45.4

NV
71.9
55.8
37.5
80.9
208.0
10.7
80.5
166.7
114.6
240.2
48.3
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AA
117.2
62.3
35.1
77.0
203.8
11.7
90.0
208.9
122.5
233.6
49.2

AV
56.7
62.9
33.2
72.1
198.2
13.0
99.9
130.1
101.3
161.5
47.5

Table 4.1E. mRNA levels encoding proteins involved in glycan degradation.

Gene Name
ArylsulfataseA
ArylsulfataseB
alpha-GalactosidaseA
beta-Galactosidase(lactase)
b-Galactosidase
b-Glucuronidase(Gus-s)
hexosaminidaseA
Hyaluronidase1
Hyaluronidase2
a-L-iduronidase
Acida1_4Glucosidase
AcidLipase
AcidSphingomyelinase
alpha-N-Acetylglucosaminidase
Asah
Cystinosis
Galactosylceramidase
Glucocerebrosidase(gba)
MPI
N-Aspartyl-b-Glucosaminidase
protectiveproteinforbeta-galactosidase
SialicAcidTransportProteinLAMP1
SialicAcidTransportProteinLAMP2
a-Mannosidase(Man2B1)
b-Mannosidase
MannosidaseII(Man2A1/ManII)
acylneuraminatelyase
a-N-Acetyl-Galactosaminidase
GM2ActivatorProtein
Neu1
Neu2
Neu3
Galactosamine-6-Sulfatase
IduronateSulfatase
SULF1
SULF2
N-sulfoglucosaminesulfohydrolase

NA
NV
AA
AV
259.3 197.6 258.3 176.3
61.4
63.5
61.1
68.2
177.5 183.5 155.1 172.2
51.5
55.2
51.4
57.2
354.0 271.2 296.5 207.8
356.6 344.0 311.1 228.3
274.1 238.5 328.4 242.5
63.2
66.4
59.5
47.6
304.3 267.2 206.5 181.2
197.0 196.7 212.6 232.2
481.1 311.0 644.0 515.1
186.2 165.4 208.5 184.9
754.7 823.6 1308.2 1831.2
151.2 112.6 168.6 135.2
461.4 431.2 567.2 408.6
178.3 166.8 170.2 151.6
37.9
38.6
34.6
40.6
428.1 270.9 385.4 217.3
456.9 578.7 419.7 773.8
591.2 480.7 783.9 391.3
854.5 820.4 1025.1 865.6
2931.2 3159.6 3297.9 3629.8
489.3 303.0 474.3 276.8
406.6 307.7 366.3 299.4
320.1 332.0 302.6 257.5
279.4 192.9 298.3 165.2
154.9 125.6 123.0 182.4
245.4 177.5 237.0 143.0
248.5 215.0 269.9 199.6
182.1 170.8 183.7 179.3
67.6
64.6
73.1
57.7
125.0 137.7 157.5 183.5
109.5
88.7
96.0
74.8
50.2
59.6
64.9
77.0
727.8 389.2 677.6 251.2
864.6 939.4 695.5 401.4
66.2
68.3
72.5
72.4
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Table 4.1F. mRNA levels encoding proteins involved in nucleotide sugar synthesis and transport.

Gene Name
CMP-sialicacid
UDP-Galactosetransporter
UDP-galactosetransporterrelated
UDP-GlcNActransporter
CMP-N-acetylneuraminicacidsynthase
CMP-Neu5Achydroxylase
epimerase
Fucose-1-phosphateguanylyltransferase
galactokinase(galK)
Galactose-1-phosphateuridylyltransferase
GDPfucosesynthetase
GDP-man4-6dehyd
GDP-mannosepyrophosphorylaseA
GlcNAc/ManNAckinase
GlcNAc2-epimerase
glucosamine-6phosphatedeaminase/isomerase
glucosamine-phosphateN-acetyltransferase
glucosephosphateisomerase
Glutamine-fructose-6phosphatetransaminase1
Glutamine-fructose-6phosphatetransaminase2
hexokinase1
ketohexokinase(fructokinase)
Neu5Ac9-phosphatesynthase
PAPSsynthetase-1
PAPSsynthetase-2
phosphoglucomutase1
phosphomannomutase
phosphomannomutase1
pyrophosphorylase
UDP-Gal-4-Epimerase
UDP-GlucoseDehydrogenase
UDP-GlucuronicacidDecarboxylase
uridinediphosphoglucosepyrophosphorylase2
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NA
272.9
154.6
1157.0
107.7
813.5
66.6
213.6
87.5
295.8
332.7
155.0
142.7
409.6
348.7
330.1

NV
238.9
147.9
1057.4
115.9
561.8
72.1
159.3
88.6
293.8
514.0
151.1
107.5
293.4
372.4
310.0

AA
178.5
173.6
791.7
90.9
714.7
97.6
196.2
96.4
174.0
441.0
150.0
112.4
628.3
270.9
381.8

AV
174.4
156.1
884.7
81.7
585.7
94.0
116.4
82.8
151.1
631.7
222.0
80.0
363.7
297.2
325.9

146.5

175.9

160.7

171.3

167.2
3481.4

175.8
3577.7

114.8
3231.8

105.0
3325.8

227.9

271.7

249.0

380.3

65.7

70.0

96.3

137.3

915.5
134.2
320.7
407.2
75.2
821.8
156.0
185.6
622.6
86.8
565.9
144.2
515.9

963.7
121.8
293.4
395.7
75.6
1341.0
166.4
151.9
503.4
83.3
358.3
130.2
543.3

648.3
155.1
188.2
211.2
105.2
741.4
234.7
187.4
589.9
78.0
452.7
142.0
386.1

737.8
171.7
146.7
150.9
75.9
1767.4
305.4
163.7
621.1
65.8
165.0
153.3
700.7

five of the seven O-glycan associated enzymes do not change. Of the O-glycan
associated enzymes that do change (Galnt1 and Galnt2), Galnt1 is upregulated
in the atria compared to the ventricle of both neonatal and adult tissues and
Galnt2 is higher in the adult tissues.

Terminal Structures
Core glycan structures are elongated, and often, branches are added
contributing to variation of N-glycan structures that differs among cell types
(Comelli et al.86 and addressed in chapter 5). Extracellular communication and
any modulatory effects of glycans are likely due not only to structural variation,
but also, and possibly more importantly, to terminal residues. Not surprisingly,
terminal glycosyltransferase expression is highly variable from tissue to tissue.
Tables 4.1B, 4.1C and 4.1D illustrate these changes in sialyltransferase,
sulfotransferase and fucosyltransferase expression among the four tissues.

Glycan Degradation
Glycan degradation enzymes are intimately involved in glycan biosynthesis as
displayed in (Figure 1.4). Removal of glucose and mannose residues allows Nglycosylation to proceed in the endoplasmic reticulum and golgi apparatus after
the structure is transferred from dolichol to asparagine of a glycoprotein.
Incomplete or improper removal of these glucose and mannose structures leads
to improper glycosylation structures and likely a pathological disorder such as
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CDG. It should also be noted that degradases included in the GLYCOv2 chip are
active at various time points of the glycan lifetime including in the lysosome. As
summarized in table 4.1E, the expression of glycan degradases varies among all
tissues with no discernible pattern. Each tissue is the highest expresser of at
least one gene and the lowest expresser of others.

Nucleotide Sugar Synthesis and Transporters
Enzymes classified under the category of nucleotide sugar synthesis have a role
in creating and transporting the sugars that glycosyltransferases add to the
glycan structure. These enzymes include transporters that bring the sugars into
the proper organelle, epimerases, isomerases, synthases and other enzymes
directly involved in nucleotide sugar synthesis. These proteins and their relative
expression levels are summarized in table 4.1F which shows varying expression
of these genes and that all three expression patterns are present.

Tissue Type Comparison
Chamber and developmental effects can be elucidated using four comparison
groups: neonatal atria (NA) vs neonatal ventricle (NV), NA vs adult atria (AA), AA
vs adult ventricle (AV), and NV vs AV. The two remaining comparison groups:
NA vs AV and AA vs NV are neither chamber specific or developmental
comparisons and were excluded from this analysis.
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Figure 4.4A. Glycosylatransferases differentially expressed throughout the
developing myocardium.
NA NV AA AV

NA

NV

AA

AV

Figure 4.4. Differential expression of glycogenes directly involved in glycan
synthesis; (A) glycosyltransferases, (B) glycan degradases, and (C) nucleotide
sugar synthesis and transporters. Left panel shows expression relationships of
all glycogenes in each category. Right panel shows glycogenes considered to be
differentially expressed at p<0.01.
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Figure 4.4B. Glycan degradses differentially expressed throughout the
developing myocardium.
NA

NV

AA

AV

NA

NV

AA

AV
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Figure 4.4C. Nucleotide sugar synthesis and transporters differentially
expressed throughout the developing myocardium.
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Figure 4.5. Differential expression of glycogenes by category.
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Figure 4.5. Each comparison group shows the % of genes within a type of
glycogene that were found to be differentially expressed. (A) Differential
expression patterns when all four tissue types are compared. (B) and (C) show
the chamber specific differences in neonate and adult respectively. (D) and (E)
reveal the developmental changes in glycogene expression by category. Note
the patterns of all comparisons are unique.

Glycogene expression is largely different in each of the four comparison
groups and is detailed below. Overall, 419 of the 710 genes are differentially
expressed in at least one comparison group. These changes are summarized in
figures 4.4 and 4.5 which reveals that the proportion of differentially expressed
genes is higher than any single comparison group; indicating that one
comparison group does not encompass all differentially expressed
genes. Surprisingly, the three gene groups directly involved in glycosylation
(glycosyltransferases, glycan degradases and those involved in nucleotide sugar
synthesis and transport) show that ~46% (110 of 239) of these genes are
differentially expressed at p<0.01 (Figure 4.4) among the four myocyte types.

Glycogene expression profiles of two tissue types were compared to attempt to
identify major developmental and chamber specific changes. Table 4.2
summarizes these changes and shows overall changes between groups and the
changes in specific glycogene categories. These data, together with the
heatmap data (Figure 4.2 and 4.4), identify a large proportion of overall gene
expression changes between tissue types. Specific details of differential
expression with each relevant myocyte comparison group is discussed below.

Chamber-Specific Regulation
Neonatal Atria and Ventricle
Expression of glycogene targets in the neonate varies between the atria and
ventricle. Specifically, expression of 161 of 710 (22.7%) gene targets are
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Table 4.2. Differential glycogene expression profile

Glycantransferase
Glycan
Degradation
Nucleotide Sugar
Synthesis and
Transport
CBP:C-Type
Lectin
CBP:I-Type Lectin
CBP:S-Type
Lectin
Glycoprotein
Notch pathway
Intracellular
protein transport
Adhesion
Molecule
Chemokine
Cytokine
Growth Factors &
Receptors
Interleukin &
Receptors
Proteoglycan

NA:NV

AA:AV

AA:NA

AV:NV

Totals

n

%

n

%

n

%

n

%

31

16.4

50

26.5

22

11.6

52

27.5

189

10

25.6

20

51.3

5

12.8

18

46.2

39

8

22.2

15

41.7

10

27.8

20

55.6

36

15

13.8

32

29.4

17

15.6

37

33.9

109

3

18.8

5

31.3

1

6.3

4

25.0

16

3

21.4

5

35.7

3

21.4

6

42.9

14

2

20.0

4

40.0

0

0.0

2

20.0

10

7

31.8

5

22.7

4

18.2

6

27.3

22

0

0.0

1

14.3

0

0.0

1

14.3

7

4

50.0

3

37.5

2

25.0

4

50.0

8

6

9.8

8

13.1

9

14.8

24

39.3

61

1

7.1

2

14.3

1

7.1

5

35.7

14

45

25.3

56

31.5

30

16.9

52

29.2

178

4

9.1

8

18.2

7

15.9

12

27.3

44

12

40.0

11

36.7

9

30.0

14

46.7

30

Table 4.2. Summary of the differential expression of glycogenes by category.
Both the number and the overall percent of glycogenes differentially expressed
are displayed (p<0.05).
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significantly altered (p<0.05). Interestingly, 118 of the 161 (73%) differentially
expressed gene targets are expressed at higher levels in the neonatal ventricle.
Furthermore, of the genes where expression is considered to be highly different
(>1.3-fold change), the proportion remains at approximately 73% (100 gene
targets) are in the ventricle. When the p-value is decreased to 0.01, 99 genes
are still considered differentially expressed. Differences in glycogene expression
between atria and ventricles are evidence of the importance of minor
adjustments required for proper cellular function (discussed further in chapter 6).

Adult Atria and Ventricle
The second chamber specific comparison between the adult atria and ventricle
shows another large change in glycogene target expression with 253 of the 710
targets (35.6%) altered. Within this comparison, 39.1% of the differentially
expressed gene targets are up-regulated in the atria. These figures are modified
only slightly when only highly altered (>1.3-fold change) gene targets are
analyzed with 36.7% (66 gene targets) of the highly differentially expressed gene
targets are in the atria.

Developmental Regulation
Adult and Neonatal Atria
Glycogene expression between neonatal and adult atria indicates that 19.4%
(p<0.05) (138 of 710 gene targets) of gene targets are significantly differentially
expressed. 55.1% of these genes are up-regulation in the adult atria compared
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to the neonatal atria. Of the highly differentially expressed genes (>1.3 fold
change), these proportions remain approximately the same at 56% and 46%
respectively.

Adult and Neonatal Ventricle
The largest change in glycogene target expression is found between neonatal
and adult ventricle. 307 of 710 (43.2%) gene targets were significantly
differentially expressed with approximately an equal number of gene targets upregulated in the neonatal (154 gene targets) and adult (153 gene
targets) ventricles. Among the highly altered gene targets (>1.3 fold change),
neonatal ventricle has higher expression of 115 gene targets compared to 108
for the adult ventricle.

Quantitative PCR verifies microarray data
Gene chip verification is an important process for quality control and duplication
of expression levels. Here, we verified each comparison group using three
distinct genes for each comparison for a total of twelve. These included
sialyltransferases involved in N-glycan synthesis or O-glycan synthesis and
growth factors. Tissue type comparisons of the expression of each of the
twelve glycogenes are consistent with genechip findings compared to HPRT
(Figure 4.6). These data were also analyzed by comparing expression levels to
β-actin as the control with similar results (data not shown).
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Figure 4.6. qPCR validates the GeneChip microarray data.
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Figure 4.6. Selected genes were investigated by qPCR analysis of RNA to
validate GeneChip microarray data. Three glycogenes from each comparison
group were studied, revealing that data from both microarray and qPCR were
consistent. All genes were normalized to the endogenous control gene, HPRT.
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Discussion
Glycogene expression is a developmentally regulated process in the myocardium
with large changes in both the developing atria and ventricle. Significant
differences are apparent within the developing atria with 19.4% of the genes
differentially expressed yet the developing ventricle shows more than twice as
many genes differentially expressed at 43.2%.

Not surprisingly, glycogene expression is significantly regulated between cardiac
chambers. Differential expression of glycogenes between chambers at the same
developmental stage range from 22.7% (neonates) to 35.6% (adults) suggesting
that glycan structures are modified between chambers.

Glycogene expression is differently regulated among the four myocyte types
indicating that the glycome is remodeled throughout the developing myocardium.
The high levels of variation among the four comparison groups provides insight
into the possible changes in glycan structure at a cellular level.
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CHAPTER 5
THE GLYCOME IS REMODELED THROUGHOUT THE HEART DURING
DEVELOPMENT

With such diversity in glycogene expression, one would expect very
different populations and relative quantities of glycans synthesized by the cell.
Mass spectrometry is a powerful tool for identifying the populations of glycans
present in a given sample. The resulting spectra provide insight into changes in
N-glycan profiles produced throughout the developing heart. Complete mass
spectra are shown in figures 5.1 and 5.2.

High Mannose Structures
The intensity patterns of the first five major high mannose structures (1579, 1783,
1987, 2192 and 2369) are almost identical among all four tissue samples:
neonatal atria, neonatal ventricle, adult atria and adult ventricle (blue peaks,
Figures 5.1 and 5.3). The high mannose structure at m/z 2369 is the most
common structure of the five high mannose structures and is most common
overall in three of the four tissues composing over 50% of the total glycan
density. The adult atria is the exception with the high mannose structures
composing only 23.5% of the total glycan population (Table 5.1). When
comparing the pattern of only high mannose structures, m/z 1987 is the least
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Figure 5.1A. The population of N-glycans is different among the four myocyte
types.
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Figure 5.1. (A) Mass Spectrometry profiles of N-glycans in neonatal and adult
atria and ventricles utilizing MALDI-TOF MS. . Note that the lower MW
structures up to high mannose structures are at relatively high density for each
myocyte type (blue peaks). Significant variation in complex glycan structures
among myocyte types is readily apparent (red peaks), both in relative levels and
types of glycans. Predicted glycan structures for highlighted peaks are shown in
neonatal ventricle panel. (B and C) N-glycans associated with masses reported
in figure 1A. (B) Glycans with masses between 1500 and 3050 m/z, (C)
structures with masses above 3050 m/z. Structures that list the mass in
highlighted yellow ovals were determined using MALDI TOF/TOF analyses. Blue
square, GlcNAc; green circles, mannoe; yellow circles, glucose; red diamonds,
NeuAc; light blue diamonds, NeuGc; red triangles, fucose.
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Figure 5.1B. Identified low mass N-glycan structures and their relative mass.
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Figure 5.1C. Identified high mass N-glycan structures and their relative mass.
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Figure 5.2A. Mass spectra of the neonatal atrial N-glycans.

Figure 5.2. MALDI-TOF mass spectra for each tissue type. Each spectrum is an
enlarged version of those displayed in figure 5.1 to better show detail. Masses
correspond to structures in figure 5.1B and 5.1C.
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Figure 5.2B. Mass spectra of the neonatal ventricular N-glycans.

86

Figure 5.2C. Mass spectra of the adult atrial N-glycans.
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Figure 5.2D. Mass spectra of the adult ventricular N-glycans.
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Figure 5.3. Mass spectra of masses between 1500 and 2400 m/z.

Figure 5.3. Enlarged schematic of spectra between 1500 and 2400 m/z. The
blue peaks indicate relative density of high mannose structures.
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Figure 5.4. Mass spectra of masses between 2400 and 3050 m/z.

Figure 5.4. Enlarged schematic of spectra between 2400 and 3050 m/z. The red
peaks indicate relative density of bi-antennary structures assigned to one of three
groups.
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Figure 5.5. Spectra of masses above 3050 m/z.

Figure 5.5. Enlarged schematic of spectra above 3050 m/z. These peaks are
associated with the most complex and highest mass structures.
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Table 5.1. Relative percentage of glycan structures defined by either structure
(high mannose) or mass.
NA

NV

AA

AV

High Mannose

52.06

60.43

23.53

52.95

2400-3050 m/z

37.63

23.24

57.38

35.91

3050-5000 m/z

1.45

8.98

10.44

1.37

Table 5.1. Relative density of glycan structures defined by either structure (high
mannose) or mass. Note the low proportion of high mannose glycans and high
proportion of higher mass structures in the adult atria (AA) compared to all other
groups. Although relative density of glycans in the neonatal atria (NA) and adult
ventricle (AV) are similar, the mass spectra are much different as seen in figure
5.1, 5.2A and 5.2D. Neonatal ventricle, NV.
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common while 1783 and 2192 are higher and similar in level of expression in all
tissue types.

Complex Structures
Complex structures, defined here as those structures that have been processed
beyond high mannose stages and have a mass above 2400 m/z, are present in
unique relative quantities among all four tissue types. The structures with
masses between 2400 and 3050 m/z are bi-antennary complex structures
(Figure 5.4) while those with masses above 3050 m/z are mostly tri- and tetraantennary (Figure 5.5).

Chamber-specific glycan profile changes
Neonatal Atria and Ventricle
The neonatal atria and ventricle spectra are surprisingly similar in terms of
glycans present or absent, yet the level of each glycan varies. The neonatal atria
have higher relative levels of almost every glycan between 2400 and 3050 m/z
accounting for approximately 37.6% of the overall glycan population compared to
23.2% for the neonatal ventricle (Table 5.1). Of particular interest in this region
are three sets of sialylated glycans (Figure 5.4):

group 1 consists of glycans at 2605 and 2635 m/z,
group 2 is composed of glycans at 2793, 2822 and 2852 m/z and
group 3 is comprised of glycans at 2966, 2996 and 3026 m/z.
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In the neonatal atria and ventricles, groups 1 and 3 decrease in relative level
from low m/z to high m/z and group 2 increases in relative glycan level from low
m/z to high m/z.

The greater number of unique higher mass (above 3050 m/z) N-glycan structures
are present in the neonatal ventricle with several complex structures produced by
the ventricle but not the atria (Figure 5.5). In the higher mass region the relative
abundance is higher in the ventricle accounting for 8.9% in contrast to 1.4% in
the neonatal atria (Table 5.1). Thus, it is likely that the neonatal atria produce the
same bi-antennary structures as the ventricle but at a higher relative abundance
while the neonatal ventricle produce more tri- and tetra- antennary structures at
higher relative levels than the neonatal atria.

Adult Atria and Ventricle
The population of glycans present in the adult atria and ventricle are comparable
in some manners and different in others. Note for the adult atria, the data are
normalized to the 2852.2 m/z peak whereas the other three tissue types are
normalized to the high-mannose structure around 2396 m/z (Figure 5.1). Despite
this change, the spectral patterns between 2400 and 3050 m/z for adult atria and
ventricle are very similar with adult atria showing higher (57.4% compared to
35.9%) relative levels of each glycan (Table 5.1). Groups 1, 2 and 3 are similar
in pattern in that the relative level increases from low to high m/z; although, the
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adult ventricle has extremely low relative expression levels of 2793 and 2822 m/z
(i.e., barely greater than baseline (Figure 5.4)).

Higher mass structures are present in greater relative abundance and number of
species in the adult atria than in the adult ventricle (Figure 5.5). The most
complex glycan registers with a minor peak at 3867.2 in the adult ventricle, yet
the adult atria had a higher relative level of the glycan at that mass and six
glycans register at a higher mass than 3867.2. These high mass structures
compose approximately 10.4% of the adult atria overall glycan population
compared to 1.4% for the adult ventricle (Table 5.1).

Developmental glycan profile changes
Neonatal and Adult Atria
In contrast to the similarities of age matched comparisons, developmental
differences are more apparent. The putative structure of middle mass, biantennary glycan structures present are similar throughout atrial development but
with much higher relative levels in the adult atria for most structures (Figure 5.4).
One major exception is the glycan at 2809 m/z which is the highest peak above
2397 in the neonatal atria whereas this peak is relatively minor in the adult atria.
Groups 1 and 3 show opposite patterns with neonatal atria decreasing relative
levels from low to high m/z and adult atria increasing relative levels from low to
high m/z. Surprisingly, group 2 has an identical pattern in both neonatal and
adult atria with increasing relative levels from to low to high m/z.
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The higher mass range of both adult and neonatal atria has similar glycan
structures, yet each tissue type has some structures that are unique (Figure
5.5). The relative levels of these glycans is higher in the adult atria with over
10% of glycan structures with higher mass than 3050 m/z compared to neonatal
atria with higher mass composing only approximately 1.4% of the total glycan
structures (Table 5.1).

Neonatal and Adult Ventricle
The developmental changes between adult and neonatal ventricle are prominent
in the mass spectra shown in figure 5.1. The portion of glycans in the 2400 to
3050 m/z range is much higher in the adult ventricle (35.9%) compared to the
neonatal ventricle (23.2%), but the pattern of expression is also changed (Table
5.1). Groups 1 and 3 have opposite patterns with the neonatal ventricle
increasing relative level from low to high m/z and adult decreasing relative level
from low to high m/z (Figure 5.4). Group 2 has an identical pattern in both adult
and neonatal ventricle.

In contrast, the neonatal ventricles have a much higher proportion (8.9%) of
glycans in the higher mass range than the adult ventricle (1.4%) (Table 5.1). The
neonatal ventricle also has 37 unique high mass glycan structures compared to
the adult ventricle with only 13 (Figure 5.4). This change indicates a shift
towards bi-antennary glycans in the adult ventricle.
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Discussion
Regulated glycogene expression throughout the heart during development would
lead one to expect the glycan profile to also be markedly varied among myocyte
types. In fact, each tissue has a unique glycan profile with notable similarities
among all tissues. All tissues have an identical pattern of the identified high
mannose structures indicating that high mannose structure production is similar
in all four tissues. The microarray data correlates quite well that expression
levels of enzymes responsible for high mannose synthesis and pruning are
comparable across the four tissue types.

There are over 30 different forms of sialic acid produced in nature. In the mouse
there are two common sialic acids attached to glycans, N-acetylneuraminic acid
(NeuAc) and N-glycolylneuraminic acid (NeuGc). These sialic acids seem to be
developmentally regulated in mouse myocardium. Adult tissues seem to produce
glycans that add NeuGc preferentially over NeuAc, as shown in groups 1, 2 and
3. Alternatively, this conclusion cannot be made in the neonates since the
dominant peak in these groups varies between those with NeuAc (groups 1 and
3) and NeuGc (group 2). These changes are examples of the developmental
modifications of glycan structures.

Glycan profiles are markedly different among the four tissue types tested in two
of the three glycan mass categories with only the high mannose patterns being
similar among the four tissue types. Changes in glycan profiles among the four
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tissues are prevalent above 2400 m/z indicating that the modifications in glycan
structure are imposed in the latter steps of the glycosylation pathway. Biantennary glycans are similar in structure throughout the developing
myocardium, yet the relative levels of these glycans change in both in a
developmental and chamber-specific manner. Furthermore, the largest
variations in the number of glycan structures are at a mass above 3050
m/z where tri- and tetra-antennary structures are located. The glycogene
expression data are consistent with these data in that the majority of glycogenes
active in the distal golgi apparatus are most commonly differentially expressed.
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CHAPTER 6
THE REGULATED EXPRESSION OF A SINGLE
POLYSIALYLTRANSFERASE IMPACTS CARDIAC EXCITABILITY

Sialic acid residues are the primary terminal residues and are added to the
glycan structure through sialyltransferase activity. Through polysialyltransferase
activity, the level of sialylation is greatly increased. Polysialyltransferase
enzymes are responsible for addition of sialic acids to sialic acids creating long
chains from 5 to 100 residues termed polysialic acid. Expression of the
polysialyltransferase, ST8 alpha-N-acetyl-neuraminide alpha-2,8sialyltransferase 2 (STX), is highly regulated in the developing myocardium. As
seen in chapter 4, STX is expressed at much higher levels in the neonatal atria
compared to the neonatal ventricle, adult atria and ventricle where STX is
essentially not expressed. To ascertain whether a single enzyme whose
expression is regulated may affect cardiac excitability, we recorded action
potentials from control and STX knockout mice. The results of these studies
indicated that Nav function may be modified by the regulated expression of STX
thereby altering atrial action potentials. Here, we also question whether the
regulated expression of a single sialyltransferase is sufficient to alter Nav gating.
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The effects of sialic acid residues on the voltage dependence of voltage gated
sodium channel (Nav) gating has been extensively studied 117,118,120,123. Thus far,
it has been determined that sialic acid residues modulate ion channels in an
alpha (pore-forming) subunit manner and through the expression of the auxillary
subunit, β1. For Nav, the mechanism by which sialic acids modulate channel
gating is through an apparent electrostatic attraction between the negative
surface potential (to which the negatively charged sialic acid residues contribute)
and the positively charged amino acids of the channel's voltage sensors
117,118,120,123

. Stocker and Bennett determined that the sodium channel isoform

expressed in neonatal ventricles was less-sialylated compared to the same
sodium channel isoform in the neonatal atria, adult atria and ventricle indicating
another possible mechanism for the cell to manipulate channel gating through
changing the glycans attached to the proteins123. In this study, we have identified
large changes in glycogene expression and glycan structure; consistent with a
global mechanism by which cardiac function is altered by a regulated glycome.

The neonatal atrial action potential waveform is altered when STX is absent
To question whether the regulated expression of a single sialyltransferase can
alter cardiac excitability, action potential waveforms were recorded from neonatal
atria and ventricles of control and STX knockout mice. Proper voltage-gated
sodium, potassium and calcium channels are essential to initiate and propagate
the action potential in cardiomyocytes. Neonatal atrial action potential recordings
reveal a rate of depolarization (dV/dt) that is 65% slower in the knockout atria
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Figure 6.1. Expression of STX modifies neonatal atrial, but not ventricular AP
waveform.

Atria

Ventricle

+ STX - STX + STX - STX
dV/dt (normalized)
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Figure 6.1. Measured parameters of the action potential waveform. Bar graphs
of the mean +_ S.E.M. (A) The rate of action potential depolarization. (B) The
maximum AP depolarization. (C) Representative action potential traces from
STX control (red) and knockout (blue) atria.
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compared to the littermate control atria (Figure 6.1). The maximal depolarization
of the knockout atria is also 30 mV less than the control atria as determined by
peak amplitude (Figure 6.1). These two measurements tend to be associated
with the portions of the action potential produced by sodium currents and are
consistent with how Nav dysfunction changes excitability with STX expression.
That is, the lack of STX expression in the knockout would cause the channel to
gate at more depolarized potentials. These changes lead to a slower action
potential depolarization rate. Because the time to reach peak amplitude is
increased in the absence of STX, a higher percentage of Kv may be active at the
peak of the action potential. Increased K+ currents during the rising phase of the
action potential would offset Na+ currents and effectively decrease the peak
amplitude. No changes in action potential waveform were observed in ventricular
myocytes; as expected since STX is not expressed in the ventricle.

The voltage dependence of Nav gating changes only in the neonatal atria of
the STX knockout.
To determine whether the absence of a single sialyltransferase, STX, can modify
Nav gating, Na+ currents were recorded from atrial and ventricular myocytes
isolated from STX knockout mice and compared to littermate controls. Neonatal
tissues are ideal to elucidate whether STX can modulate Nav gating since STX is
expressed several times more abundantly in the atria than in the ventricle and
both tissues are isolated from the heart of the same animal. The Nav Va and Vi
measured in the knockout atrial myocyte were 7-9 mV more depolarized and
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Normalized Conductance

Figure 6.2. STX causes a change in neonatal atrial Nav activation voltage, but
not in ventricular Nav activation.
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Figure 6.2. Conductance-voltage relationships for control and STX knockout
atrial and ventricular Nav. Data are the mean normalized peak conductance ±
S.E.M. Representative current traces are shown to the right.
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Figure 6.3. STX causes a change in neonatal atrial Nav steady state inactivation,
but not in ventricular Nav steady state inactivation.
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Figure 6.3. Steady-state availability curves for control and STX knockout atrial
and ventricular Nav. Data are the mean normalized current ± S.E.M.
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Figure 6.4. Absence of STX causes a slowing of the neonatal atrial Nav
inactivation rate, but has no effect on the kinetics of ventricular Nav inactivation.
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Figure 6.4. Inactivation kinetics for control and STX knockout atrial and
ventricular Nav. Data are the mean time constant of inactivation ± S.E.M.
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Time constant for
recovery from fast inactivation (ms)

Figure 6.5. Absence of STX increases the rate of recovery from fast inactivation
for neonatal atrial Nav to rates similar to those measured for control and knockout
ventricular Nav.
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Figure 6.5. Recovery from inactivation kinetics of for control and STX knockout
atrial and ventricular Nav. Data are the mean time constant of recovery from
inactivation ± S.E.M. Significance (p < 0.05) demarcated with an *. Lack of
significance demarcated with an #.
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Table 6.1. Measured action potential and Nav parameters.

Control
Atria

Knockout
Atria

Control
Ventricle

Knockout
Ventricle

1.00±0.12

0.35±0.03*

1.00±0.41

1.02±0.28#

137.2±4.8

111.9±7.5*

125.6±10.7

127.6±10.2#

Nav Va (mV)

-55.6±1.7

-48.3±1.1*

-53.8±3.2

-50.7±1.3#

Nav Vi (mV)

-105.1±1.2

-96.7±1.4*

-92.9±3.5

-90.0±1.2#

Nav τh (ms)

1.73±0.17

2.93±0.37*

2.85±0.29

2.48±0.24#

Nav τrec (ms)

9.47±0.57

6.71±0.68*

6.29±0.33

6.90±0.80#

dV/dt
(normalized)
Maximal
Depolarization
(mV)

Table 6.1. The measured action potential and Nav gating parameters measured
for control and STX knockout cardiomyocyte Nav. The data are the mean
parameter values ± S.E.M. τh data were measured at -50 mV and τrec data were
measured at -120 mV. Significance was determined using a two-tailed Student’s
t test comparing control atria and ventricles to STX knockout atria and ventricles,
respectively. Significance (p<0.04) demarcated with an *. Lack of significance
demarcated with an #.
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control atrial Va and Vi (figures 6.2 and 6.3). No significant difference in
ventricular Nav steady state gating was observed (figures 6.2 and 6.3). The Nav
kinetic gating properties are again consistent with the steady state parameters.
That is, no shift in neonatal ventricular Nav gating kinetics were observed, but
neonatal atrial Nav kinetics were shifted in the depolarized direction in the
absence of STX (Figures 6.4 and 6.5). Collectively, these data reveal the
impact of a single glycogene on Nav function.

Discussion
Alterations of the measured action potential properties are consistent with the
changes measured in Nav gating in the neonatal atria. Shifting the Va to more
depolarized potentials require a greater depolarization to elicit an action potential.
Thus, there is a higher proportion of Nav that are closed as the membrane
depolarizes which leads to the slower rate of depolarization (dV/dt) observed.
Further, the activation of some Kv channels would cause both a slower rate of
depolarization and a smaller maximal depolarization as the outward delayed
rectifier K+ current would counteract membrane depolarization by the inward Na+
current. Finally, the more depolarized Vi would cause Nav to inactivate possibly
before maximal depolarization; therefore, decreasing Na+ current and reducing
the rate of depolarization and maximal depolarization.

The glycome is remodeled between the neonatal atria and ventricle as shown in
the two previous chapters. Here, we showed that the changing glycome may
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alter cardiac excitability by modulating action potential waveforms and Nav
function. These data are consistent with our recent study in neonatal rats which
revealed a sialic acid dependent shift in Nav gating parameters in the neonatal
atrial myocytes but no shift in ventricular Nav gating123. Nav of control neonatal
atria which expresses STX at relatively high levels, gate at a hyperpolarized
potential compared Nav gating observed in the STX knockout atrial myocytes.
Consistent with the Nav data, AP waveform parameters are altered between the
control and knockout STX atrial cardiomyocytes while ventricular myocytes
action potentials show no significant change with STX expression.

The slower rates of depolarization and lower peak amplitude seen in the STX
knockout atria compared to the control atria are consistent with another study in
which cardiomyocyte glycosylation was altered73. This study indicated a role for
glycosylation in heart failure as studied in a mouse model in which the muscle
LIM protein (MLP) is absent. MLP is not associated with glycosylation, yet
cardiomyocytes are under-glycosylated compared to control. MLP knockout and
neuraminidase-treated myocytes show altered action potential parameters as
mentioned above as well as shifts in the voltage-dependence of gating
comparable with those currents recorded here.

Together, Nav and action potential data reveal that changing the expression of a
single glycogene can significantly modify cardiac excitability. For this study, we
observed the impact of the regulated expression of STX on cardiac excitability,
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yet this is only one of the >100 glycogenes that are differentially expressed in the
developing heart. If a single enzyme can have this impact on cardiac excitability,
the potential of a remodeled glycome on cardiac function is likely substantial.

110

CHAPTER 7
FINAL DISCUSSION

This study describes two mechanisms by which Nav function and cardiomyocyte
excitability can be modulated through differential glycosylation. The first
mechanism, the protein-isoform specific mechanism, indicates that the cell can
express combinations of protein isoforms that have similar functions, but are
differently glycosylated. This differential glycosylation affects channel function
and thereby alters the action potential waveform. The second mechanism, the
cell-specific glycosylation mechanism, describes how the change in glycan
structure through regulation of glycogene expression in a cell-specific manner.

The first portion of this project focused on Nav and the manner in which alpha
subunit function can be modified by the β1 isoform. Different combinations of α
and β subunits will likely function differently than other combinations giving the
cell the ability to slightly alter Nav function. Ten α and four β Nav isoforms have
been identified and, as shown in chapter 3, β1 modulated each α subunit function
differently.

Nav alpha subunits show isoform-specific sensitivity to negatively charged sialic
acid residues. When expressed in the CHO cell line, no significant shift in the
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voltage dependence of Nav1.2 and Nav1.7 gating was observed in this study.
Previously, Nav1.5 was shown to be sialic acid insensitive; whereas, Nav1.4 is
sensitive to sialic acids attached to the alpha subunit. Interestingly, the β1
subunit modifies the voltage dependence of Nav gating in a subunit specific
manner. Three of the less-glycosylated Nav α isoforms tested were modulated
by β1 sialic acids, yet Nav1.4 was insensitive to any effect of β1 in the CHO cell
expression system. Furthermore, when the less-glycosylated Nav1.4 chimera
was co-expressed with β1, it became sensitive to β1 modulation. Together, these
data indicate that alpha and/or β1 sialylation modulates Nav gating in a saturating
manner.

The modulation of Nav gating by β1 was abolished when co-expressed in the
non-sialylating Lec2 cell line; likewise, β1 was unable to modulate gating of any
alpha subunit isoform when the β1 N-glycosylation sites were mutated. Thus, the
effect of β1 can be attributed entirely to the glycans attached. We conclude that
β1 modulated Nav gating in a sialic acid dependent, saturating manner.

With each alpha subunit having a unique glycosylation signature, changing which
alpha subunit is expressed could result in a sialic acid dependent shift in channel
voltage dependence. Four beta subunits likely modulate alpha subunit gating
through various mechanisms - as we have shown here, β1 modulates gating
through glycosylation, but the three remaining beta isoforms may alter channel
gating through other, glycosylation dependent or independent mechanisms. A
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recent report described this exact effect with the β2 subunit. Johnson and
Bennett reported that β2 caused a sialic acid dependent hyperpolarizing shift in
Nav1.5 gating while β2 caused a sialic acid independent depolarizing shift in the
voltage dependence of Nav1.2 gating121. Co-expression of both β1 and β2 with
each α subunit revealed an additive effect. Nav1.5.β1.β2 produced a larger
hyperpolarizing shift in gating; whereas, Nav1.2.β1.β2 gated like Nav1.2 alone.
These differences in the manner in which β1 and β2 impact α subunit gating
indicates that expression of various combinations of alpha and beta subunits
would create an array of voltages at which the channel gates.

In vivo, Nav alpha and beta isoform expression may be up- or down-regulated in
response to development or pathologies, and this could result in a sialic acid
dependent change in the voltage dependence of Nav gating. Theoretically, Nav
gating can be modulated in hundreds of ways through unique combinations of
differently glycosylated alpha and beta subunits. Nav1.5 is the primary Nav
isoform expressed in both chambers of the developing heart. However, in the
developing skeletal muscle, the Nav α isoform changes from Nav1.5 in the
neonate to Nav 1.4 in the adult183-185. The adult skeletal muscle isoform is heavily
glycosylated compared to the neonatal isoform 117,118. As previously reported,
the Nav1.4 gating is sialic acid sensitive while Nav1.5 is insensitive to sialic acid
modulation when expressed in CHO cells118. β1 is developmentally regulated in
the rodent heart where it is highly expressed in the adult ventricle, but expressed
at much lower levels in the neonatal atria and ventricle and adult atria123.
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Expression of various combinations of α and auxillary subunits may create a
spectrum of channel gating parameters that are glycosylation dependent; thus,
supporting the relevance of the protein-specific mechanism by which Nav function
is modulated.

As described, the second mechanism studied here questioned whether cell
specific change in glycogene expression and the corresponding changes in
glycan structure are relevant to Nav gating. Glycogene expression varies
widely between cardiac chambers and through development with over 46% of
glycosylation-associated genes differentially expressed. Comparison of neonatal
and adult ventricular myocyte glycogene expression showed the highest
proportion of differential expression at 43.2% while the neonatal and adult atria
showed the lowest at 19.4%. Corresponding to these changes in glycogene
expression, we report large changes in N-glycan structures throughout the
developing myocardium.

Mass spectrometry of the cardiomyocyte glycans throughout development
showed major differences in glycan structure between each myocyte comparison
group. All groups had similar ratios of high mannose structures. However, there
was marked variation throughout the developing myocardium in the more
complex structures above 2400 m/z. The adult atria had the highest proportion
of complex N-glycans of any myocyte type (mass ranges of 2400-3050 and
3050-5000 m/z). Neonatal atria and adult ventricle had comparable levels of N114

glycans in the 3050-5000 m/z and were the lowest relative levels of the four
tissues studied. In addition, the structures of these glycans varied among
myocyte types, with each tissue having at least one unique glycan. Observations
derived from these data support a second mechanism by which glycosylation
might impact cardiac function, through cell-specific regulation of glycosylation.
That is, the GeneChip and glycan screening data indicate that the glycome is
remodeled throughout the myocardium and during development.

These studies have led to a proposed model that predicts that gating of Nav is
modulated by glycans through two mechanisms (Figure 7.1). The left panel
describes the "protein isoform-mediated" mechanism which is controlled at the
transcriptional level where alpha and beta subunit isoforms are expressed. Each
alpha subunit has a unique glycosylation signature creating currents unique to
the combination of alpha and beta isoforms.

The right panel shows the model for the "cell-specific glycosylation" mechanism
of modulation. Here, the glycogene profile determines the glycan structures
present and how sodium currents are modulated by the remodeled glycome.
The neonatal and adult atria and ventricles express the same Nav α subunit
isoform yet apparently have unique glycan structures which cause the channels
to gate differently. Tight control of glycogene expression is essential for cells to
consistently produce appropriate glycans for that cell's particular function. Minor
changes in glycogene expression may alter glycan structure and therefore
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Figure 1. Model proposing glycosylation-dependent control and modulation of
Nav gating.

Figure 1. This model describes two mechanisms by which a cell can modulate
Nav gating. The protein-specific (left panel) and the cell-specific glycosylation
(right panel) mechanisms together create a spectrum of possible channel gating
motifs (bottom panel).
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change the manner in which glycans mediate cell adhesion, self vs. non-self
recognition, molecular trafficking, receptor activation and even modulate cellular
excitability. We find here that slight changes in glycan structure, specifically
changing sialic acid levels, could alter sodium channel function (as characterized
by the G-V curves shown in figure 6.1). Hundreds of possible sodium channel GV curves would result following these slight changes in glycan composition.
Combination of these two mechanisms would create a spectrum of Nav that gate
at various voltages.

Although both mechanisms describe means by which sodium channel function
may be modified, there may be examples in which one of the two mechanisms is
dominant. In the dorsal root ganglion (DRG), there is an apparent change in the
level of glycosylation of Nav 1.9 through development186. The DRG expression
of Nav1.9 does not change, yet the level of glycosylation is greater in the neonate
compared to adult. This study also showed a functional impact of glycosylation
on Nav gating with approximately a 7 mV depolarizing shift in Vi in the adult
compared to neonate. When treated with neuraminidase (an enzyme that
removes sialic acid residues), this voltage shift was abolished. Unlike other
studies, no effects on activation were identified, indicating that glycosylation may
impact gating of Nav in an isoform dependent manner.

In this study we showed that a single polysialyltransferase, STX, is expressed
essentially only in the neonatal atria. In the absence of STX, both Nav function
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and action potential parameters were altered in neonatal atrial myocytes. No
modulation of Nav gating or action potential waveform was observed in neonatal
ventricular myocytes; consistent with the fact that STX is not expressed in the
ventricle. In wild type atrial myocytes, STX must be important for proper
excitability and other possible processes not studied here. This further supports
the model presented above that slight alterations in glycosylation may alter
channel function in a cell-specific manner since the same Nav α subunit is
expressed in the neonatal atria and ventricles.

Changing the expression of a single glycogene can have dramatic effects upon
cellular excitability as shown with STX in the neonatal atria. Therefore, if one of
more than 100 regulated glycogenes can alter cardiac excitability, the potential
impact of the remodeled glycome on cardiac function is considerable; not only on
cardiac excitability, but on a range of cardiac processes.

Significance of this study
The broad role of glycans in normal and pathophysiological processes demands
tight control of glycans present on cell surfaces that may differ from cell to cell
and from tissue to tissue. Glycans are essential to regulate protein folding, cell
adhesion, molecular trafficking and clearance, receptor activation, endocytosis
and signal transduction. Furthermore, glycans determine blood type and
immunity.
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Through understanding differential glycosylation of cells and tissues, we better
understand normal function and the dysfunction associated with
pathophysiological conditions. Drug side effects are a result of the drug
disrupting the normal physiological process in a system not associated with the
target system88,89. Improving the effectiveness of a drug and preventing side
effects is a main goal in therapeutic research. Targeting glycans may allow
researchers to obtain this goal. Because each tissue expresses a unique
population of glycans, therapeutics can be developed that use glycans to target
specific tissues for drug delivery.

Altered glycans are a hallmark of the tumor phenotype. Cancer cells over- and
under- express naturally occurring glycans and expression of glycans restricted
to embryonic tissues 88. Furthermore, if the embryonic glycan forms could be
modified to elicit an immune response to the tumor, a side-effect free, effective
cancer therapeutic would be developed.

Cardiac arrhythmias are associated with various ion channel maladies. Several
reports indicate point mutations of Nav1.5 cause aberrant inactivation leading to a
persistent sodium current which can lead to LQTS by creating inward sodium
current in phase 2 of the cardiac action potential 129,171. Persistent sodium
current would counteract the outward rectifying K+ current, extending the phase
2 of the cardiac action potential and the QT segment of ECG. By shifting the Va
to more hyperpolarized potentials, Nav will open following lesser depolarizations,
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thus limiting extension of phase 2 and LQTS. Although new methods of
modifying glycans are currently under investigation, several methods may be
used to modify sodium channel function including gene therapy which may
involve either mechanism explained above. First, glycosyltransferase DNA could
be delivered to the cell which could directly increase sialylation (via STX for
example) or increase glycan branching and overall sialylation. Second, auxiliary
subunits may be expressed to modify Nav function.

The goal of this work was to identify and explain a model by which glycans can
modulate activity of proteins (specifically Nav) and how this may influence cardiac
excitability. Furthermore, we explained the vast changes in glycogene
expression and glycan structures that occur throughout the developing
myocardium and how the regulated expression of a single polysialyltransferase
modulates cardiac excitability. Pathological and stressor mediated (i.e. cigarette
smoke) studies in all organ systems might be studied in a similar manner to
better understand the changes in the glycome and excitability that these
conditions induce. Through further research and development of glycan focused
and glycan mediated therapeutics, maladies caused by or marked by changes in
glycan structures may be treated.
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